CPC  COOPERATIVE PATENT CLASSIFICATION

C  CHEMISTRY; METALLURGY
(NOTES omitted)

CHEMISTRY

C12  BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMEOLOGY; MUTATION OR GENETIC ENGINEERING
(NOTES omitted)

C12N  MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing microorganisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from microorganisms or animal material A01N 63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS (preservation of living parts of humans or animals A01N 1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q)

NOTES
1. Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes.
2. Attention is drawn to Notes (1) to (3) following the title of Class C12.
3. When classifying in this group, classification is also made in group B01D 15/08 insofar as subject matter of general interest relating to chromatography is concerned.

WARNINGS
1. The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:
   - C12N 1/11 covered by C12N 15/79
   - C12N 1/13 covered by C12N 15/79
   - C12N 1/15 covered by C12N 15/80
   - C12N 1/19 covered by C12N 15/81
   - C12N 1/21 covered by C12N 15/74
   - C12N 5/02 covered by C12N 5/00, C12N 5/04 - C12N 5/166
   - C12N 5/07 - C12N 5/095 covered by C12N 5/06 and subgroups
   - C12N 5/18 - C12N 5/28 covered by C12N 5/16 and subgroups
   - C12N 5/18 covered by C12N 5/16
   - C12N 5/20 covered by C12N 5/163
   - C12N 5/22 covered by C12N 5/16
   - C12N 5/24 covered by C12N 5/163
   - C12N 5/26 covered by C12N 5/166
   - C12N 5/28 covered by C12N 5/166
   - C12N 7/01 covered by C12N 7/00
   - C12N 9/02-C12N 9/08 covered by C12N 9/2408
   - C12N 9/26 covered by C12N 9/2408
   - C12N 9/28-C12N 9/30 covered by C12N 9/2408
   - C12N 9/32 covered by C12N 9/2468
   - C12N 9/34 covered by C12N 9/2434
   - C12N 9/36 covered by C12N 9/2451
   - C12N 9/38 covered by C12N 9/2434
   - C12N 9/40 covered by C12N 9/2451
   - C12N 9/42 covered by C12N 9/2451
   - C12N 9/44 covered by C12N 9/2451
   - C12N 9/46 covered by C12N 9/2451
   - C12N 9/56 covered by C12N 9/2451
   - C12N 9/66 covered by C12N 9/2451
   - C12N 9/68 covered by C12N 9/2451

CPC - 2019.02
2. In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the scheme.
Microorganisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from microorganisms A61K 35/66; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines A61K 39/00); Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor

1/005 . . . [after treatment of microbial biomass not covered by C12N 1/02 - C12N 1/06]
1/02 . Separating microorganisms from their culture media
1/04 . Preserving or maintaining viable microorganisms (immobilised microorganisms C12N 11/00)
1/06 . Lysis of microorganisms
1/063 . . . (of yeast)
1/066 . . . (by physical methods)
1/08 . Reducing the nucleic acid content
1/10 . Protozoa; Culture media therefor
1/12 . Unicellular algae; Culture media therefor (as new plants A01H 13/00)
1/14 . Fungi (culture of mushrooms A01G 18/00; as new plants per se A01H 15/00); Culture media therefor
1/16 . . . Yeasts; Culture media therefor
1/18 . . . Baker’s yeast; Brewer’s yeast
1/20 . . Bacteria ((bacteria per se C12R 1/01 - C12R 1/64); Culture media therefor
1/22 . . Processes using, or culture media containing, cellulose or hydrolysates thereof
1/24 . . Processes using, or culture media containing, waste sulfite liquor
1/26 . . Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using microorganisms C10G 32/00)
1/28 . . . aliphatic
1/30 . . . having five or less carbon atoms
1/32 . . Processes using, or culture media containing, lower alkanols, i.e. C1 to C6
1/34 . . Processes using foam culture
1/36 . Adaptation or attenuation of cells
1/38 . Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N 1/34 takes precedence)

Spore forming or isolating processes

3/00

Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H 4/00)

NOTE

In this group, the following words are used with the meanings indicated:

• a “multipotent” cell is restricted to one lineage;
• “progenitor” and “precursor” cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.

5/006 . . . (Modification of the membrane of cells, e.g. cell decoration)
5/0012 . . . (Cell encapsulation)
5/0018 . . . (Culture media for cell or tissue culture (media for specific animal cell type C12N 5/06))
5/0025 . . . (Culture media for plant cell or plant tissue culture)
5/0031 . . . (Serum-free culture media)

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to C12N 5/0037 - C12N 5/0056

5/0037 . . . (Serum-free medium, which may still contain naturally-sourced components)
5/0043 . . . (Medium free of human- or animal-derived components)
5/005 . . . (Protein-free medium)
5/0056 . . . (Xeno-free medium)
5/0062 . . . (General methods for three-dimensional culture)
5/0068 . . . (General culture methods using substrates (for specific animal cell type C12N 5/06))
5/0075 . . . (using microcarriers)
5/0081 . . . (Purging biological preparations of unwanted cells)
5/0087 . . . (Purging against subsets of blood cells, e.g. purging alloreactive T cells)
5/0093 . . . (Purging against cancer cells)
5/04 . . . Plant cells or tissues [(culture media C12N 5/0025)]
5/06 . . . (Animal cells or tissues; Human cells or tissues (preservation of living cells or tissues A01N 1/02); Not used, see subgroups)

NOTE

In this group, the following words are used with the meanings indicated:

• a “totipotent” cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
• a “pluripotent” cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
• a “multipotent” cell is restricted to one lineage.

“Progenitor” and “precursor” cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells

5/0601 . . . (Invertebrate cells or tissues, e.g. insect cells; Culture media therefor)
5/0602 . . . {Vertebrate cells}

**NOTE**
Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

5/0603 . . . {Embryonic cells (production of embryos, nuclear transfer A01K 67/027); Embryoid bodies}

5/0604 . . . {Whole embryos; Culture medium therefor}

5/0605 . . . {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}

5/0606 . . . {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N 5/0611), induced pluripotent stem cells C12N 5/0696)

5/0607 . . . {Non-embryonic pluripotent stem cells, e.g. MSC (induced pluripotent stem cells C12N 5/0696)

5/0608 . . . {Germ cells (production of embryos, nuclear transfer A01K 67/027); Not used, see subgroups}

5/0609 . . . {Oocytes, oogonia (fertilised oocytes C12N 5/0604)

5/061 . . . {Sperm cells, spermatogonia

5/0611 . . . {Primordial germ cells, e.g. embryonic germ cells [EG]

5/0612 . . . {sorting of gametes, e.g. according to sex or motility

5/0613 . . . {Cells from endocrine organs (pancreas C12N 5/0676, gonads C12N 5/0681)

5/0614 . . . {Adrenal gland

5/0615 . . . {Pineal gland

5/0616 . . . {Pituitary gland

5/0617 . . . {Thyroid and parathyroid glands

5/0618 . . . {Cells of the nervous system

5/0619 . . . {Neurons

5/062 . . . {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain

5/0621 . . . {Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N 5/062)

5/0622 . . . {Gial cells, e.g. astrocytes, oligodendrocytes; Schwann cells

5/0623 . . . {Stem cells

5/0625 . . . {Epidermal cells, skin cells; Cells of the oral mucosa

5/0626 . . . {Melanocytes

5/0627 . . . {Hair cells

5/0628 . . . {Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N 5/0666)

5/0629 . . . {Keratinocytes; Whole skin

5/063 . . . {Keratinocyte stem cells; Keratinocyte progenitors

5/0631 . . . {Mammary cells

5/0632 . . . {Cells of the oral mucosa

5/0633 . . . {Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands

5/0634 . . . {Cells from the blood or the immune system

**NOTE**
Committed progenitors are classified with their progeny

5/0635 . . . {B lymphocytes

5/0636 . . . {T lymphocytes

5/0637 . . . {Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)

5/0638 . . . {Cytotoxic T lymphocytes (CTL), lymphokine activated killer cells [LAK]

5/0639 . . . {Dendritic cells, e.g. Langherhans cells in the epidermis

5/064 . . . {Immunosuppressive dendritic cells

5/0641 . . . {Erythrocytes

5/0642 . . . {Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells

5/0643 . . . {Osteoclasts

5/0644 . . . {Platelets; Megakaryocytes

5/0645 . . . {Macrophages, e.g. Kuepfer cells in the liver; Monocytes

5/0646 . . . {Natural killers cells [NK], NKT cells

5/0647 . . . {Haematopoietic stem cells; Uncommitted or multipotent progenitors

5/0648 . . . {Splenocytes

5/065 . . . {Thymocytes

5/0651 . . . {Lymph nodes

5/0652 . . . {Cells of skeletal and connective tissues; Mesenchyme

5/0653 . . . {Adipocytes; Adipose tissue

5/0654 . . . {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth

5/0655 . . . {Chondrocytes; Cartilage

5/0656 . . . {Adult fibroblasts

5/0657 . . . {Cardiomyocytes; Heart cells

5/0658 . . . {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts

5/0659 . . . {Satellite cells

5/066 . . . {Tenocytes; Tendons, Ligaments

5/0661 . . . {Smooth muscle cells

5/0662 . . . {Stem cells

5/0663 . . . {Bone marrow mesenchymal stem cells (BM-MSC)

5/0664 . . . {Dental pulp stem cells, Dental follicle stem cells

5/0665 . . . {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood

5/0666 . . . {Mesenchymal stem cells from hair follicles

5/0667 . . . {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

5/0668 . . . {Mesenchymal stem cells from other natural sources

5/0669 . . . {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647, C12N 5/0666)

5/067 . . . {Hepatocytes

5/0671 . . . {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

5/0672 . . . {Stem cells; Progenitor cells; Precursor cells; Oval cells

5/0676 . . . {Pancreatic cells
WARNING

Enzymes and Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K 8/66, A61Q 11/00; medicinal preparations containing enzymes or proenzymes A61K 38/43; enzyme containing detergent compositions C11D; enzymes with nucleic acid structure, e.g. ribozymes, C12N 15/113); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C 1/00)

NOTE

Cells modified by introduction of foreign genetic material [Not used, see subgroups]

7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K 59/00)

7/02 Recovery or purification
7/04 Inactivation or attenuation; Producing viral sub-units
7/05 [Three-dimensional culture, tissue culture or organ culture; Encapsulated cells]
7/06 [Stem cells; Progenitor cells; Precursor cells]
7/08 [Cells of the gastro-intestinal tract]
7/09 [Stem cells; Progenitors]
5/10 [Cells of the genital tract; Non-germinal cells from gonads; Not used, see subgroups]
5/12 [Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0690)]
5/14 [Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/0611)]
5/16 [Cells of the urinary tract or kidneys]
5/18 [Bladder epithelial cells]
5/20 [Kidney cells]
5/22 [Renal stem cells; Renal progenitors]
5/24 [Cells from the lungs or the respiratory tract]
5/26 [Stem cells; Progenitors]
5/28 [Vascular Endothelial cells]
5/30 [Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels]
5/32 [Stem cells; Progenitor cells; Precursor cells]
5/34 [Tumour cells; Cancer cells]
5/36 [Cells of blood, e.g. leukemia cells, myeloma cells]
5/38 [Stem cells; Progenitor cells; Precursor cells]
5/40 [Artificially induced pluripotent stem cells, e.g. iPS]
5/42 [Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N 5/0691)]
5/44 [Skin equivalents]
5/46 Cells modified by introduction of foreign genetic material [Not used, see subgroups]
5/48 Fused cells, e.g. hybridomas
5/50 Plant cells
5/52 Animal cells
5/53 [one of the fusion partners being a B or a T lymphocyte]
5/55 [resulting from interspecies fusion]
7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K 59/00)

7/02 Recovery or purification
7/04 Inactivation or attenuation; Producing viral sub-units
7/06 [Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered]
7/08 [Inactivation or attenuation] by chemical treatment
7/10 [Inactivation or attenuation] by serial passage of virus
7/12 Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K 8/66, A61Q 11/00; medicinal preparations containing enzymes or proenzymes A61K 38/43; enzyme containing detergent compositions C11D; enzymes with nucleic acid structure, e.g. ribozymes, C12N 15/113); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C 1/00)

NOTE

Enzymes are generally categorized below according to the “Nomenclature and Classification of Enzymes” of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.

5/0683 . . . . [Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/0611)]
5/0685 . . . . [Cells of the gastro-intestinal tract]
5/0687 . . . . [Stem cells; Progenitors]
5/0688 . . . . [Cells of the genital tract; Non-germinal cells from gonads; Not used, see subgroups]
5/069 C12N.
9/01 Animal cells
9/03 Plant cells
9/04 Animal cells
9/06 . . . . [Stem cells; Progenitors]
9/08 . . . . [Artificially induced pluripotent stem cells, e.g. iPS]
9/10 [Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N 5/0691)]
9/12 [Skin equivalents]
9/14 Cells modified by introduction of foreign genetic material [Not used, see subgroups]
9/16 Fused cells, e.g. hybridomas
9/18 Plant cells
9/20 Animal cells
9/22 Animal cells
9/24 Animal cells
9/26 Animal cells
9/28 Animal cells
9/30 Animal cells
9/32 Animal cells
9/34 Animal cells
9/36 Animal cells
9/38 Animal cells
9/40 Animal cells
9/42 Animal cells
9/44 Animal cells
9/46 Animal cells
9/48 Animal cells
9/50 Animal cells
9/52 Animal cells
9/54 Animal cells
9/56 Animal cells
9/58 Animal cells
9/60 Animal cells
9/62 Animal cells
9/64 Animal cells
9/66 Animal cells
9/68 Animal cells
9/70 Animal cells
9/72 Animal cells
9/74 Animal cells
9/76 Animal cells
9/78 Animal cells
9/80 Animal cells
9/82 Animal cells
9/84 Animal cells
9/86 Animal cells
9/88 Animal cells
9/90 Animal cells
5/0687 . . . . [Cells of the genital tract; Non-germinal cells from gonads; Not used, see subgroups]
Transferases (2.) (ribonucleases C12N 9/22

- [acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)]
- [acting on paired donors with incorporation of molecular oxygen (1.14)]
- [with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13]
- [Nitric-oxide synthase (1.14.13.39)]
- [with a reduced iron-sulfur protein as one donor (1.14.15)]
- [Steroid 11 beta monoxygenase (P-450 protein)(1.14.15.4)]
- [Cholesterol monoxygenase (cytochrome P450csc)(1.14.15.6)]
- [Steroid 17 alpha-monoxygenase (1.14.99.9)]

- [Steroid 21-monoxygenase (1.14.99.10)]
- [acting on superoxide as acceptor (1.15)]
- [acting on CH or CH\(_2\) groups (1.17)]
- [acting on iron-sulfur proteins as donor (1.18)]
- [acting on reduced flavodoxin as donor (1.19)]
- [acting on iron-sulfur proteins as donor (1.18)]
- [acting on CH or CH\(_2\) groups (1.17)]
- [acting on distilled flavodoxin as donor (1.19)]

- [Transferases for other substituted phosphate groups (2.7.3)]
- [Transferases for other substituted phosphate groups (2.7.4)]
- [Phosphotransferases with paired acceptors (2.7.9)]

- [acting on enzymes containing groups (2.8)]
- [Hydrolases (3)]
- [acting on ester bonds (3.1)]
- [Carboxylic ester hydrolases (3.1.1)]
- [acting on CH or CH\(_2\) groups (3.2.1)]

- [acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)]
- [Lysozyme (3.2.1.17)]
- [acting on alpha-1,6-glucosidic bonds]
- [Dextranase (3.2.1.11)]
- [acting on beta-1,4-glucosidic bonds]
- [Beta-amylase (3.2.1.2)]
- [Glucan 1,4-alpha-glucosidase from plant source]
- [Glucan 1,4-alpha-glucosidase from fungal source]
- [Glucan 1,4-alpha-glucosidase from bacterial source]

- [acting on alpha,1,4-glycosidic bonds]
- [acting on alpha,1,6-glycosidic bonds]
- [acting on alpha-1,4-glycosidic bonds]
- [acting on alpha-1,6-glycosidic bonds]

- [acting on alpha-1,4-glycosidic bonds]
- [acting on alpha-1,6-glycosidic bonds]
- [acting on alpha-1,4-glycosidic bonds]
- [acting on alpha-1,6-glycosidic bonds]

- [acting on alpha-1,4-glycosidic bonds]
- [acting on alpha-1,6-glycosidic bonds]
- [acting on alpha-1,4-glycosidic bonds]
- [acting on alpha-1,6-glycosidic bonds]
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>9/48</td>
<td>proteinases, e.g. endopeptidases (3.4.21-3.4.25)</td>
</tr>
<tr>
<td>9/49</td>
<td>hydrolyzing N-glycosyl compounds (3.2.2)</td>
</tr>
<tr>
<td>9/50</td>
<td>proteinases, e.g. endopeptidases (3.4.21-3.4.25)</td>
</tr>
<tr>
<td>9/51</td>
<td>hydrolyzing N-glycosyl compounds (3.2.2)</td>
</tr>
<tr>
<td>9/52</td>
<td>derived from bacteria or archaebacteria</td>
</tr>
</tbody>
</table>

**WARNING**

- Group C12N 9/50 is impacted by recategorization into group C12N 9/52.
- Groups C12N 9/50 and C12N 9/52 should be considered in order to perform a complete search.

**NOTE**

- In this group, archaebacteria, formerly known as archaebacteria, are classified with bacteria.

**WARNING**

- Group C12N 9/52 is incomplete pending recategorization of documents from group C12N 9/50.
- Groups C12N 9/50 and C12N 9/52 should be considered in order to perform a complete search.

9/54 derived from bacteria being Bacillus
9/58 derived from fungi
9/60 from yeast
9/62 from Aspergillus
9/63 from plants
9/64 from animal tissue
9/6402 from non-mammals
9/6405 not being snakes
9/6408 serine endopeptidases (3.4.21)
9/641 cysteine endopeptidases (3.4.22)
9/6413 aspartic endopeptidases (3.4.23)
9/6416 metalloendopeptidases (3.4.24)
9/6418 from snakes
9/6421 from mammals
9/6424 serine endopeptidases (3.4.21)
11/00 Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof

11/02 . . . Enzymes or microbial cells being immobilised on or in an organic carrier
11/04 . . . entrapped within the carrier, e.g. gel, hollow fibre
11/06 . . . attached to the carrier via a bridging agent
11/08 . . . carrier being a synthetic polymer
11/10 . . . carrier being a carbohydrate
11/12 . . . . Cellulose or derivatives thereof
11/14 . . . Enzymes or microbial cells being immobilised on or in an inorganic carrier
11/16 . . . Enzymes or microbial cells being immobilised on or in a biological cell
11/18 . . . Multi-enzyme systems

13/00 Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

15/00 Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms); per se C12N 1/00, C12N 5/00, C12N 7/00; new plants per se A01H: plant reproduction by tissue culture techniques A01H 4/00; new animals per se A01K 67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K 48/00

15/01 . . . Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
15/02 . . . Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion (monoclonal antibodies C07K 16/00; apparatus for cell fusion C12M)
15/03 . . . Bacteria
15/04 . . . Fungi
15/09 . . . Recombinant DNA-technology
15/10 . . . Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H 21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P 19/34)

NOTE

After the symbol C12N 15/10 - C12N 15/106, and separated therefrom by a + sign, it is desirable to add the indexing codes selected from groups C12Q 2500/00 - C12Q 2565/634, relating to relevant technical features of the invention. When more than one indexing code is selected, the different codes are separated by a + sign. Example: C12N 15/1037 + C12Q 2537/125 + C12Q 2521/537

15/1006 . . . . [by means of a solid support carrier, e.g. particles, polymers]
15/101 . . . . [by chromatography, e.g. electrophoresis, ion-exchange, reverse phase]
15/1013 . . . . [by using magnetic beads]
15/1017 . . . . [by filtration, e.g. using filters, frits, membranes]
15/1012 . . . . [Mutagenizing nucleic acids]
15/1024 . . . . [In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair]
15/1027 . . . . [by DNA shuffling, e.g. RS, STEP, RPR]
15/1031 . . . . [mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR]
15/1034 . . . . [Isolating an individual clone by screening libraries]
15/1037 . . . . [Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display]
15/1041 . . . . [Ribosome/Polyosome display, e.g. SPERT, ARM]
15/1044 . . . . [Preparation or screening of libraries displayed on scaffold proteins]
15/1048 . . . . [SELEX]
15/1051 . . . . [Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors]
15/1055 . . . . [Protein x Protein interaction, e.g. two hybrid selection]
15/1058 . . . . [Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms]
15/1062 . . . . [mRNA-Display, e.g. polypeptide encoding template are connected covalently]
15/1065 . . . . [Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM- mutagenesis, tagged polynucleotides, gene tags]
15/1068 . . . . [Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatic DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis NRPS, DNA/RNA-polymerase mediated polypeptide synthesis]
15/1072 . . . . [Differential gene expression library synthesis, e.g. subtracted libraries, differential screening]
15/1075 . . . . [by coupling phenotype to genotype, not provided for in other groups of this subclass]
15/1079 . . . . [Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N 15/1086)]
15/1082 . . . . [Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors]
15/1086 . . . . [Preparation or screening of expression libraries, e.g. reporter assays]
15/1089 . . . . [Design, preparation, screening or analysis of libraries using computer algorithms]
15/1093 . . . [General methods of preparing gene libraries, not provided for in other subgroups]

15/1096 . . . [cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR]

15/11 . . . DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H 21/00); [Non-coding nucleic acids having a biological activity]

**NOTE**
Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups C12N 15/11 - C12N 15/117 cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The C12N 2303/00 ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group C12N 15/111

15/111 . . . [General methods applicable to biologically active non-coding nucleic acids]

15/113 . . . Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex-forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N 15/8218)}

15/1131 . . . [against viruses]

15/1132 . . . [against retroviridae, e.g. HIV]

15/1133 . . . [against herpetoviridae, e.g. HSV]

15/1135 . . . [against oncogenes or tumor suppressor genes]

15/1136 . . . [against growth factors, growth regulators, cytokines, lymphokines or hormones]

15/1137 . . . [against enzymes {viral enzymes C12N 15/1131; receptors C12N 15/1138}]

15/1138 . . . [against receptors or cell surface proteins]

15/115 . . . Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith; {Nucleic acids binding to non-nucleic acids, e.g. aptamers]

**NOTE**
Aptamers fused to compounds which are already classified in groups C12N 15/11 - C12N 15/117, are classified with the corresponding compound

15/117 . . . Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs

15/52 . . . Genes encoding for enzymes or proenzymes

**NOTE**
In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.

15/62 . . . DNA sequences coding for fusion proteins

**NOTE**
In this group, the following term is used with the meaning indicated:
• "fusion" means the fusion of two different proteins.

15/625 . . . [containing a sequence coding for a signal sequence]

15/63 . . . Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

15/635 . . . [Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracycline]

15/64 . . . General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

15/65 . . . using markers (enzymes used as markers C12N 15/52)

15/66 . . . General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

**NOTE**
In this group, the following expression is used with the meaning indicated:
• "non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.

15/67 . . . General methods for enhancing the expression

15/68 . . . . Stabilisation of the vector

15/69 . . . Increasing the copy number of the vector

15/70 . . . Vectors or expression systems specially adapted for E. coli

**NOTES**
1. This group covers the use of E. coli as host.
2. Shuttle vectors also replicating in E. coli are classified according to the other host.

15/71 . . . Expression systems using regulatory sequences derived from the trp-opener

15/72 . . . Expression systems using regulatory sequences derived from the lac-opener

15/73 . . . Expression systems using phage (lambda) regulatory sequences

15/74 . . . Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonomospora

**NOTE**
This group covers the use of prokaryotes as hosts.
10/8216 . . . . . . {Methods for controlling, regulating or enhancing expression of transgenes in plant cells}
10/8217 . . . . . . {Gene switch}
10/8218 . . . . . . {Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}
10/822 . . . . . . [Reducing position variability, e.g. by the use of scaffold attachment region/ matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression]
<table>
<thead>
<tr>
<th>CPC</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15/825</td>
<td>... involving pigment biosynthesis</td>
</tr>
</tbody>
</table>

**NOTE**
Transgenic plants with altered flower morphology are also classified in this group

<table>
<thead>
<tr>
<th>CPC</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15/8251</td>
<td>... Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis</td>
</tr>
<tr>
<td>15/8253</td>
<td>... [Methionine or cysteine]</td>
</tr>
<tr>
<td>15/8254</td>
<td>... [Tryptophan or lysine]</td>
</tr>
<tr>
<td>15/8255</td>
<td>... involving lignin biosynthesis</td>
</tr>
<tr>
<td>15/8257</td>
<td>... for the production of primary gene products, e.g. pharmaceutical products, interferon</td>
</tr>
<tr>
<td>15/8258</td>
<td>... for the production of oral vaccines (antigens) or immunoglobulins</td>
</tr>
<tr>
<td>15/8259</td>
<td>... [Phytoremediation]</td>
</tr>
<tr>
<td>15/8261</td>
<td>... with agronomic (input) traits, e.g. crop yield</td>
</tr>
<tr>
<td>15/8262</td>
<td>... involving plant development (not used)</td>
</tr>
<tr>
<td>15/8263</td>
<td>... [Ablation; Apoptosis]</td>
</tr>
<tr>
<td>15/8265</td>
<td>... [Transgene containment, e.g. gene dispersal]</td>
</tr>
<tr>
<td>15/8266</td>
<td>... [Abscission; Dehiscence; Senescence]</td>
</tr>
<tr>
<td>15/8267</td>
<td>... [Seed dormancy, germination or sprouting]</td>
</tr>
<tr>
<td>15/8269</td>
<td>... [Photosynthesis]</td>
</tr>
<tr>
<td>15/827</td>
<td>... [Flower development or morphology, e.g. flowering promoting factor [FPF]]</td>
</tr>
<tr>
<td>15/8271</td>
<td>... for stress resistance, e.g. heavy metal resistance</td>
</tr>
<tr>
<td>15/8273</td>
<td>... for drought, cold, salt resistance</td>
</tr>
<tr>
<td>15/8274</td>
<td>... for herbicide resistance</td>
</tr>
<tr>
<td>15/8275</td>
<td>... [Glyphosate]</td>
</tr>
<tr>
<td>15/8277</td>
<td>... [Phosphonitricin]</td>
</tr>
<tr>
<td>15/8278</td>
<td>... [Sulfonylurea]</td>
</tr>
<tr>
<td>15/8279</td>
<td>... for biotic stress resistance, pathogen resistance, disease resistance</td>
</tr>
<tr>
<td>15/8281</td>
<td>... for bacterial resistance</td>
</tr>
<tr>
<td>15/8282</td>
<td>... for fungal resistance</td>
</tr>
<tr>
<td>15/8283</td>
<td>... for virus resistance</td>
</tr>
<tr>
<td>15/8285</td>
<td>... for nematode resistance</td>
</tr>
<tr>
<td>15/8286</td>
<td>... for insect resistance</td>
</tr>
<tr>
<td>15/8287</td>
<td>... for fertility modification, e.g. apomixis</td>
</tr>
<tr>
<td>15/8289</td>
<td>... [Male sterility]</td>
</tr>
<tr>
<td>15/829</td>
<td>... [Female sterility]</td>
</tr>
<tr>
<td>15/8291</td>
<td>... [Hormone-influenced development]</td>
</tr>
<tr>
<td>15/8293</td>
<td>... [Abscisic acid [ABA]]</td>
</tr>
<tr>
<td>15/8294</td>
<td>... [Auxins]</td>
</tr>
<tr>
<td>15/8295</td>
<td>... [Cytokinins]</td>
</tr>
<tr>
<td>15/8297</td>
<td>... [Gibberellins; GA3]</td>
</tr>
<tr>
<td>15/8298</td>
<td>... [Brassinosteroids]</td>
</tr>
<tr>
<td>15/85</td>
<td>... for animal cells</td>
</tr>
</tbody>
</table>

**NOTE**
Additional aspects of the modified animals are classified in the groups A01K 2207/00 - A01K 2267/00

<table>
<thead>
<tr>
<th>CPC</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15/8509</td>
<td>... for producing genetically modified animals, e.g. transgenic</td>
</tr>
</tbody>
</table>

**WARNING**
From March 15, 2012 groups C12N 15/861 - C12N 15/869 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00-C12N 2795/00

<table>
<thead>
<tr>
<th>CPC</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15/861</td>
<td>... Adenoviral vectors</td>
</tr>
<tr>
<td>15/8613</td>
<td>... [Chimaeric vector systems comprising heterologous sequences for production of another viral vector]</td>
</tr>
<tr>
<td>15/8616</td>
<td>... [Special methods for targeting systems]</td>
</tr>
<tr>
<td>15/863</td>
<td>... Poxviral vectors, e.g. entomopoxvirus</td>
</tr>
<tr>
<td>15/8633</td>
<td>... [Avian poxviral vectors]</td>
</tr>
<tr>
<td>15/8636</td>
<td>... [Vaccinia virus vectors]</td>
</tr>
<tr>
<td>15/864</td>
<td>... Parvoviral vectors, e.g. parvovirus, densovirus</td>
</tr>
<tr>
<td>15/8645</td>
<td>... [Adeno-associated virus]</td>
</tr>
<tr>
<td>15/866</td>
<td>... Baculoviral vectors</td>
</tr>
<tr>
<td>15/867</td>
<td>... Retroviral vectors</td>
</tr>
<tr>
<td>15/8673</td>
<td>... [Special methods for packaging systems]</td>
</tr>
<tr>
<td>15/8676</td>
<td>... [Special methods for targeting systems]</td>
</tr>
<tr>
<td>15/869</td>
<td>... Herpesviral vectors</td>
</tr>
<tr>
<td>15/8695</td>
<td>... [Herpes simplex virus-based vectors]</td>
</tr>
<tr>
<td>15/87</td>
<td>... Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation</td>
</tr>
</tbody>
</table>
15/873 . . . Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
15/877 . . . Techniques for producing new mammalian cloned embryos
15/8771 . . . (Bovine embryos]
15/8772 . . . (Caprine embryos]
15/8773 . . . (Ovine embryos]
15/8775 . . . (Murine embryos]
15/8776 . . . (Primate embryos]
15/8777 . . . (Rabbit embryos]
15/8778 . . . (Swine embryos]
15/88 . . . using microencapsulation, e.g. using [amphiphile] liposome vesicle
15/89 . . . using microinjection
15/895 . . . [using biolistic methods]
15/90 . . . Stable introduction of foreign DNA into chromosome
15/902 . . . [using homologous recombination]
15/905 . . . (in yeast]
15/907 . . . (in mammalian cells]

2303/00 Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids

NOTE

Indexing codes of group C12N 2303/00 are only used in combination with group C12N 15/111

2310/00 Structure or type of the nucleic acid

2310/10 . Type of nucleic acid
2310/11 . Antisense
2310/111 . spanning the whole gene, or a large part of it
2310/113 . targeting other non-coding nucleic acids, e.g. antagomirs

2310/12 . catalytic nucleic acids, e.g. ribozymes
2310/121 . Hammerhead
2310/122 . Hairpin
2310/123 . Hepatitis delta
2310/124 . based on group I or II introns
2310/1241 . Tetrahymena
2310/126 . involving RNase P
2310/127 . DNAzymes
2310/128 . processing or releasing ribozyme
2310/13 . Decoys
2310/14 . interfering N.A.
2310/141 . MicroRNAs, miRNAs
2310/15 . Nucleic acids forming more than 2 strands, e.g. TFOs
2310/151 . more than 3 strands, e.g. tetrads, H-DNA
2310/152 . on a single-stranded target, e.g. fold-back TFOs
2310/153 . with the aid of a protein, e.g. recombinase
2310/16 . Aptamers
2310/17 . Immunomodulatory nucleic acids
2310/18 . acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17)
2310/20 . involving clustered regularly interspaced short palindromic repeats [CRISPRs]
2310/30 . Chemical structure
2310/31 . of the backbone
2310/311 . Phosphotriesters
2310/312 . Phosphonates
2310/315 . . . Phosphorothioates
2310/316 . . . Phosphonothioates
2310/317 . . . with an inverted bond, e.g. a cap structure
2310/318 . . . where the PO2 is completely replaced, e.g. MMI or formacetal
2310/3181 . . . Peptide nucleic acid, PNA
2310/3183 . . . Dial linkers, e.g. glycols or propanediols
2310/319 . . . linked by 2'-5' linkages, i.e. having a free 3'-position
2310/32 . . . of the sugar
2310/321 . . . 2'-O-R Modification
2310/322 . . . 2'-R Modification
2310/323 . . . modified ring structure
2310/3231 . . . having an additional ring, e.g. LNA, ENA
2310/3233 . . . Morpholino-type ring
2310/3235 . . . having the O of the ribose replaced by another atom
2310/33 . . . of the base
2310/331 . . . Universal or degenerate base
2310/332 . . . Abasic residue
2310/333 . . . Modified A
2310/334 . . . Modified C
2310/3341 . . . 5-Methylcytosine
2310/335 . . . Modified T or U
2310/336 . . . Modified G
2310/337 . . . in alpha-anomeric form
2310/34 . . . Spatial arrangement of the modifications
2310/341 . . . Gapmers, i.e. of the type ========
2310/342 . . . Hemimers, i.e. of the type =========
2310/343 . . . having patterns, e.g. ==========
2310/344 . . . Position-specific modifications, e.g. on every purine, at the 3'-end
2310/345 . . . having at least two different backbone modifications
2310/346 . . . having a combination of backbone and sugar modifications
2310/35 . . . Nature of the modification
2310/351 . . . Conjugate
2310/3511 . . . intercalating or cleaving agent
2310/3513 . . . Protein; Peptide
2310/3515 . . . Lipophilic moiety, e.g. cholesterol
2310/3517 . . . Marker; Tag
2310/3519 . . . Fusion with another nucleic acid
2310/352 . . . linked to the nucleic acid via a carbon atom
2310/3521 . . . Methyl
2310/3523 . . . Allyl
2310/3525 . . . MOE, methoxyethoxy
2310/3527 . . . Other alkyl chain
2310/3529 . . . Aromatic substituent
2310/353 . . . linked to the nucleic acid via an atom other than carbon
2310/3531 . . . Hydrogen
2310/3533 . . . Halogen
2310/3535 . . . Nitrogen
2310/3550 . . . Physical structure
2310/3551 . . . in polymeric form, e.g. multimers, concatemers
2310/3552 . . . branched
2310/3553 . . . partially self-complementary or closed
Applications; Uses
2320/00

2320/10 . in screening processes
2320/11 . for the determination of target sites, i.e. of active nucleic acids
2320/12 . in functional genomics, i.e. for the determination of gene function
2320/13 . in a process of directed evolution, e.g. SELEX, acquiring a new function
2320/30 . Special therapeutic applications
2320/31 . Combination therapy
2320/32 . Special delivery means, e.g. tissue-specific
2320/33 . Alteration of splicing
2320/34 . Allele or polymorphism specific uses
2320/35 . based on a specific dosage / administration regimen
2320/50 . Methods for regulating/modulating their activity
2320/51 . modulating the chemical stability, e.g. nuclease-resistance
2320/52 . modulating the physical stability, e.g. GC-content
2320/53 . reducing unwanted side-effects

Production
2330/00

2330/10 . naturally occurring
2330/30 . chemically synthesised
2330/31 . Libraries, arrays
2330/50 . Biochemical production, i.e. in a transformed host cell
2330/51 . Specially adapted vectors

Specific components of cell culture medium
2500/00

2500/02 . Atmosphere, e.g. low oxygen conditions
2500/05 . Inorganic components
2500/10 . Metals; Metal chelators (cobalamin
C12N 2500/38)
2500/12 . Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
2500/14 . Calcium; Ca chelators; Calcitonin
2500/16 . Magnesium; Mg chelators
2500/20 . Transition metals
2500/22 . Zinc; Zn chelators (insulin-zinc complexes
C12N 2501/33)
2500/24 . Iron; Fe chelators; Transferrin
2500/25 . Insulin-transferrin; Insulin-transferrin-selenium
2500/30 . Organic components (metal chelators
C12N 2500/10; calcitonin C12N 2500/14;
transferrin C12N 2500/24)
2500/32 . Amino acids
2500/33 . other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
2500/34 . Sugars
2500/35 . Polysols, e.g. glycerin, inositol
2500/36 . Lipids
2500/38 . Vitamins
2500/40 . Nucleotides, nucleosides, bases (cyclic
nucleotides C12N 2501/01, anti-neoplastic drugs
C12N 2501/06)
C12N 2500/42 . Organic phosphate, e.g. beta glycerophosphate
C12N 2500/44 . Thiols, e.g. mercaptoethanol

Active agents used in cell culture processes, e.g. differentiation
2501/00

NOTE
Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in C07K 14/00, but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

2501/01 . Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
2501/02 . Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
2501/03 . Compounds acting on the NO pathway, e.g. nitrososarginine
2501/04 . Immunosuppressors, e.g. cyclosporin, tacrolimus
2501/05 . Adjuvants
2501/051 . Lipid A (MPA, MPL)
2501/052 . Lipopolysaccharides [LPS]
2501/054 . Muramyl peptides
2501/056 . Immunostimulating oligonucleotides, e.g. CpG
2501/06 . Anti-neoplastic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
2501/065 . Modulators of histone acetylation
2501/07 . Heat shock proteins
2501/10 . Growth factors
2501/105 . Insulin-like growth factors [IGF]
2501/11 . Epidermal growth factor [EGF]
2501/113 . Acidic fibroblast growth factor (aFGF, FGF-1)
2501/115 . Basic fibroblast growth factor (bFGF, FGF-2)
Cytokines; Chemokines

- Colony stimulating factors (G-CSF, GM-CSF)
- Interleukins (IL)
  - Interleukin-1 (IL-1)
  - Interleukin-2 (IL-2)
  - Interleukin-3 (IL-3)
  - Interleukin-4 (IL-4)
  - Interleukin-5 (IL-5)
  - Interleukin-6 (IL-6)
  - Interleukin-7 (IL-7)
  - Interleukin-8 (IL-8)
  - Interleukin-9 (IL-9)
  - Interleukin-10 (IL-10)
  - Interleukin-11 (IL-11)
  - Interleukin-12 (IL-12)
  - Interleukin-13 (IL-13)
  - Interleukin-14 (IL-14)
  - Interleukin-15 (IL-15)
  - Interleukin-16 (IL-16)
  - Interleukin-17 (IL-17)
  - Interleukin-18 (IL-18)
  - Interleukin-19 (IL-19)
  - Interleukin-20 (IL-20)
  - Interleukin-21 (IL-21)
  - Interleukin-22 (IL-22)
  - Interleukin-23 (IL-23)
  - Interleukin-24 (IL-24)
  - Interleukin-25 (IL-25)
  - Interleukin-26 (IL-26)
  - Interleukin-27 (IL-27)
  - Interleukin-28 (IL-28)
  - Interleukin-29 (IL-29)
  - Interleukin-30 (IL-30)

- Keratinocyte growth factors (KGF-1, i.e., FGF-7; KGF-2, i.e., FGF-12)
- Other fibroblast growth factors, e.g., FGF-4, FGF-8, FGF-10
- Hepatocyte growth factor [HGF]
- Stem cell factor [SCF], c-kit ligand [KL]
- Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurtrophins [NT]; Neuregulins
- Platelet-derived growth factor [PDGF]
- Erythropoietin [EPO]
- Thrombopoietin [TPO]
- Transforming growth factor alpha [TGF-α]
- Transforming growth factor beta (TGF-β)
- Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- Activin; Inhibit; Mullerian inhibiting substance
- Vascular endothelial growth factor [VEGF]
- Angiopoietin
- Cardiotrophin
- Liver cell growth factor (LCGF, Gly-His-Lys)
- Osteoprogererin; Osteoclast differentiation factor (ODF, RANKL)
- Growth and differentiation factors [GDF]
- Heregulin, neu differentiation factor
- Chemokines, e.g., MIP-1, MIP-2, RANTES, MCP, PF-4
- Chemokines

Transcription factors

- Oct-3/4
- CD2
- B7 molecules, e.g., CD80, CD86, CD28 (ligand), Notch; Delta; Jagged; Serrate
- Hedgehog proteins; Cyclopamine (inhibitor)
- Wnt; Frizzled
- Notch; Delta; Jagged; Serrate
- Regulators of apoptosis
- Cell markers; Cell surface determinants
- CD4; CD8
- B7 molecules, e.g., CD80, CD86, CD28 (ligand), CD152 (ligand)
- CD3, T-cell receptor complex
- CD40, CD40-ligand (CD154)
- CD2
- Adhesion molecules, e.g., ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
- Integrins
- Lectins
- With CD designations not provided for elsewhere
- Transcription factors
- Sox-2
- Oct-3/4
- Kl-4
- Interferons [IFN]
- Tumour necrosing factors [TNF]
- Flt-3 ligand (CD135L, flk-2 ligand)
- Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/2501/85)
- Growth hormone [GH], aka somatotropin
- Pituitary sex hormones, e.g., follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
- Prolactin
- Angiotensins [AT], angiotensinogen
- Insulin (together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2501/105)
- Glucagon; Glucagon-like peptide (GLP); Extendin
- Calcitonin; Calcitonin-like related peptide [CGRO]; Amylin
- Gastrin; Cholecystokinin [CCK]
- Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]
- Leptin
- Somatostatin
- Endothelin
- Parathyroid hormone [PTH]
- Thyroid stimulating hormone [TSH]
- with nuclear receptors
- of the family of the retinoic acid receptor, e.g., RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- Steroid hormones
- Sexual steroids
- Thyroid hormones
- Regulators of development
- Cell cycle regulated proteins, e.g., cyclins, cyclin-dependent kinases
- Hedgehog proteins; Cyclopamine (inhibitor)
- Wnt; Frizzled
- Notch; Delta; Jagged; Serrate
- Regulators of apoptosis
- Cell markers; Cell surface determinants
- CD4; CD8
- B7 molecules, e.g., CD80, CD86, CD28 (ligand), CD152 (ligand)
- CD3, T-cell receptor complex
- CD40, CD40-ligand (CD154)
- CD2
- Adhesion molecules, e.g., ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
- Integrins
- Lectins
- With CD designations not provided for elsewhere
- Transcription factors
- Sox-2
- Oct-3/4
- Kl-4

C12N
C12N

Classification by pathway does not apply.

NOTE
Classification by pathway does not apply.

Coculture with; Conditioned medium produced by embryonic cells

NOTE
Use C12N 2501/00 to index the expressed products.
2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells

**NOTE**

This scheme indexes the starting point of a differentiation process and is used in combination with classification in C12N 5/06 for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

2506/02 . from embryonic cells
2506/025 . from extra-embryonic cells, e.g. trophoblast, placenta
2506/03 . from non-embryonic pluripotent stem cells
2506/04 . from germ cells
2506/07 . from endocrine cells
2506/072 . from adrenal cells
2506/074 . from pinealocytes
2506/076 . from pituitary cells
2506/078 . from thyroid, parathyroid cells
2506/08 . from cells of the nervous system
2506/09 . from epidermal cells, from skin cells, from oral mucosa cells
2506/091 . from melanocytes
2506/092 . from hair cells
2506/094 . from keratinocytes
2506/095 . from mammary cells
2506/097 . from oral mucosa cells
2506/098 . from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands
2506/11 . from blood or immune system cells
2506/115 . from monocytes, from macrophages
2506/13 . from connective tissue cells, from mesenchymal cells
2506/1307 . from adult fibroblasts
2506/1315 . from cardiomyocytes
2506/1323 . from skeletal muscle cells
2506/133 . from tenocytes
2506/1338 . from smooth muscle cells
2506/1346 . from mesenchymal stem cells
2506/1353 . from bone marrow mesenchymal stem cells (BM-MSC)
2506/1361 . from dental pulp or dental follicle stem cells
2506/1369 . from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
2506/1376 . from mesenchymal stem cells derived from hair follicles
2506/1384 . from adipose-derived stem cells [ADSC], from adipose stromal stem cells
2506/1392 . from mesenchymal stem cells from other natural sources
2506/14 . from hepatocytes
2506/22 . from pancreatic cells
2506/23 . from cells of the gastro-intestinal tract
2506/24 . from cells of the genital tract, from non-germinal gonad cells
2506/243 . from cells of the female genital tract cells, from non-germinal ovarian cells
2506/246 . from cells of the male genital tract cells, from non-germinal testis cells
2506/25 . from renal cells, from cells of the urinary tract
2506/27 . from lung cells, from cells of the respiratory tract
2506/28 . from vascular endothelial cells
2506/30 . from cancer cells, e.g. reversion of tumour cells

**NOTE**

Unless the tumourigenic phenotype is totally reversed, the end product is still classified under C12N 5/0693.

2506/45 . from artificially induced pluripotent stem cells

2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
2509/10 . Mechanical dissociation

2510/00 Genetically modified cells
2510/02 . Cells for production
2510/04 . Immortalised cells

2511/00 Cells for large scale production

2513/00 3D culture

2517/00 Cells related to new breeds of animals
2517/02 . Cells from transgenic animals
2517/04 . Cells produced using nuclear transfer
2517/10 . Conditioning of cells for in vitro fecondation or nuclear transfer

2521/00 Culture process characterised by the use of hydrostatic pressure, flow or shear forces
2521/10 . Sound, e.g. ultrasounds

2523/00 Culture process characterised by temperature

2525/00 Culture process characterised by gravity, e.g. microgravity

2527/00 Culture process characterised by the use of mechanical forces, e.g. strain, vibration
2529/10 . Stimulation by light

2531/00 Microcarriers

2533/00 Supports or coatings for cell culture, characterised by material
2533/10 . Mineral substrates
2533/12 . Glass
2533/14 . Ceramic
2533/18 . Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
2533/20 . Small organic molecules
2533/30 . Synthetic polymers (thermoreactive polymers, e.g. PNIPAm, C12N 2539/10)
2533/32 . Polyllysine, polynornithine
2533/40 . Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
2533/50 . Proteins
2533/52 . Fibronectin; Laminin
2533/54 . Collagen; Gelatin
2533/56 . Fibrin; Thrombin
2533/70 . Polysaccharides
C12N

2533/72 . . . Chitin, chitosan
2533/74 . . . Alginate
2533/76 . . . Agarose, agar-agar
2533/78 . . . Cellulose
2533/80 . . . Hyaluronan
2533/90 . Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
2533/92 . . . Amnion; Decellularised dermis or mucosa

2535/00 Supports or coatings for cell culture characterised by topography
2535/10 . Patterned coating

2537/00 Supports and/or coatings for cell culture characterised by physical or chemical treatment
2537/10 . Cross-linking

2539/00 Supports and/or coatings for cell culture characterised by properties
2539/10 . Coating allowing for selective detachment of cells, e.g. thermoreactive coating

2700/00 Viruses

2710/00 dsDNA Viruses (not used)
2710/00011 . dsDNA Viruses
2710/00021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/00022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/00023 . . . Virus like particles [VLP]
2710/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/00041 . . . Use of virus, viral particle or viral elements as a vector
2710/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/00043 . . . viral genome or elements thereof as genetic vector
2710/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/00045 . . . Special targeting system for viral vectors
2710/00051 . . . Methods of production or purification of viral material
2710/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/00061 . . . Methods of inactivation or attenuation
2710/00062 . . . by genetic engineering
2710/00063 . . . by chemical treatment
2710/00064 . . . by serial passage
2710/00071 . . . Demonstrated in vivo effect
2710/00088 . . . For redistribution
2710/10011 . . . Adenoviridae
2710/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences

2710/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10023 . . . Virus like particles [VLP]
2710/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10041 . . . Use of virus, viral particle or viral elements as a vector
2710/10042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10043 . . . viral genome or elements thereof as genetic vector
2710/10044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10045 . . . Special targeting system for viral vectors
2710/10051 . . . Methods of production or purification of viral material
2710/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/10061 . . . Methods of inactivation or attenuation
2710/10062 . . . by genetic engineering
2710/10063 . . . by chemical treatment
2710/10064 . . . by serial passage
2710/10071 . . . Demonstrated in vivo effect
2710/10088 . . . For redistribution
2710/10111 . . . Adenovirus, e.g. ovine adenovirus D
2710/10121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10123 . . . Virus like particles [VLP]
2710/10131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10141 . . . Use of virus, viral particle or viral elements as a vector
2710/10142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10143 . . . viral genome or elements thereof as genetic vector
2710/10144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10145 . . . Special targeting system for viral vectors
2710/10151 . . . Methods of production or purification of viral material
2710/10152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/10161 . . . . . Methods of inactivation or attenuation
2710/10162 . . . . . by genetic engineering
2710/10163 . . . . . by chemical treatment
2710/10164 . . . . . by serial passage
2710/10171 . Demonstrated in vivo effect
2710/10188 . For redistribution
2710/10211 . . . . . Aviadenovirus, e.g. fowl adenovirus A
2710/10221 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10222 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10223 . . . . . Virus like particles [VLP]
2710/10231 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10232 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10233 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10234 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10241 . . . . . Use of virus, viral particle or viral elements as a vector
2710/10242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10243 . . . . . viral genome or elements thereof as genetic vector
2710/10244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10245 . . . . . Special targeting system for viral vectors
2710/10251 . . . . . Methods of production or purification of viral material
2710/10252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/10261 . . . . . Methods of inactivation or attenuation
2710/10262 . . . . . by genetic engineering
2710/10263 . . . . . by chemical treatment
2710/10264 . . . . . by serial passage
2710/10271 . Demonstrated in vivo effect
2710/10288 . . . . . For redistribution
2710/10311 . . . . . Mastadenovirus, e.g. human or simian adenoviruses
2710/10321 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10322 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10323 . . . . . Virus like particles [VLP]
2710/10331 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10332 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10333 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10334 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10341 . . . . . Use of virus, viral particle or viral elements as a vector
2710/10342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10343 . . . . . viral genome or elements thereof as genetic vector
2710/10344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10345 . . . . . Special targeting system for viral vectors
2710/10351 . . . . . Methods of production or purification of viral material
2710/10352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/10361 . . . . . Methods of inactivation or attenuation
2710/10362 . . . . . by genetic engineering
2710/10363 . . . . . by chemical treatment
2710/10364 . . . . . by serial passage
2710/10371 . Demonstrated in vivo effect
2710/10388 . . . . . For redistribution
2710/12011 . . . . . Asfarviridae
2710/12021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/12022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/12023 . . . . . Virus like particles [VLP]
2710/12031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/12032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/12033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/12034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/12041 . . . . . Use of virus, viral particle or viral elements as a vector
2710/12042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/12043 . . . . . viral genome or elements thereof as genetic vector
2710/12044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/12045 . . . . . Special targeting system for viral vectors
2710/12051 . . . . . Methods of production or purification of viral material
2710/12052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/12061 . . . . . Methods of inactivation or attenuation
2710/12062 . . . . . by genetic engineering
2710/12063 . . . . . by chemical treatment
2710/12064 . . . . . by serial passage
2710/12071 . Demonstrated in vivo effect
2710/12088 . . . . . For redistribution
2710/14011 . . . . . Baculoviridae
Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral vectors

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Cytophaga, e.g. human herpesvirus 5

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N

2710/16134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

2710/16141 . . . . Use of virus, viral particle or viral elements as a vector

2710/16142 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule

2710/16143 . . . . viral genome or elements thereof as genetic vector

2710/16144 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector

2710/16145 . . . . Special targeting system for viral vectors

2710/16151 . . . . Methods of production or purification of viral material

2710/16152 . . . . relating to complementing cells and packaging systems for producing virus or viral particles

2710/16161 . . . . Methods of inactivation or attenuation

2710/16162 . . . . by genetic engineering

2710/16163 . . . . by chemical treatment

2710/16164 . . . . by serial passage

2710/16171 . . . . Demonstrated in vivo effect

2710/16188 . . . . For redistribution

2710/16211 . . . . Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus

2710/16221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences

2710/16222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

2710/16223 . . . . Virus like particles [VLP]

2710/16231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

2710/16232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2710/16233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

2710/16234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

2710/16241 . . . . Use of virus, viral particle or viral elements as a vector

2710/16242 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule

2710/16243 . . . . viral genome or elements thereof as genetic vector

2710/16244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector

2710/16245 . . . . Special targeting system for viral vectors

2710/16251 . . . . Methods of production or purification of viral material

2710/16252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles

2710/16261 . . . . Methods of inactivation or attenuation

2710/16262 . . . . by genetic engineering

2710/16263 . . . . by chemical treatment

2710/16264 . . . . by serial passage

2710/16271 . . . . Demonstrated in vivo effect

2710/16288 . . . . For redistribution

2710/16311 . . . . Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV

2710/16321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences

2710/16322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

2710/16323 . . . . Virus like particles [VLP]

2710/16331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

2710/16332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2710/16333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

2710/16334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

2710/16341 . . . . Use of virus, viral particle or viral elements as a vector

2710/16342 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule

2710/16343 . . . . viral genome or elements thereof as genetic vector

2710/16344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector

2710/16345 . . . . Special targeting system for viral vectors

2710/16351 . . . . Methods of production or purification of viral material

2710/16352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles

2710/16361 . . . . Methods of inactivation or attenuation

2710/16362 . . . . by genetic engineering

2710/16363 . . . . by chemical treatment

2710/16364 . . . . by serial passage

2710/16371 . . . . Demonstrated in vivo effect

2710/16388 . . . . For redistribution

2710/16411 . . . . Rhadinovirus, e.g. human herpesvirus 8

2710/16421 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences

2710/16422 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

2710/16423 . . . . Virus like particles [VLP]

2710/16431 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

2710/16432 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2710/16433 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

2710/16434 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

2710/16441 . . . . Use of virus, viral particle or viral elements as a vector

2710/16442 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule

2710/16443 . . . . viral genome or elements thereof as genetic vector
<table>
<thead>
<tr>
<th>CPC/Year</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2710/16444</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2710/16445</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2710/16451</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2710/16452</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2710/16461</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2710/16462</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2710/16463</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2710/16464</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2710/16471</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2710/16488</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2710/16511</td>
<td>Roseolovirus, e.g. human herpesvirus 6, 7</td>
</tr>
<tr>
<td>2710/16521</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2710/16522</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2710/16523</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2710/16531</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2710/16532</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytopytic agent</td>
</tr>
<tr>
<td>2710/16533</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2710/16534</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral</td>
</tr>
<tr>
<td>2710/16541</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2710/16542</td>
<td>Virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2710/16543</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2710/16544</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2710/16545</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2710/16551</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2710/16552</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2710/16561</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2710/16562</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2710/16563</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2710/16564</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2710/16571</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2710/16588</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2710/16611</td>
<td>Simplexvirus, e.g. human herpesvirus 1, 2</td>
</tr>
<tr>
<td>2710/16621</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2710/16622</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2710/16623</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2710/16631</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2710/16632</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytopytic agent</td>
</tr>
<tr>
<td>2710/16633</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2710/16634</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral</td>
</tr>
<tr>
<td>2710/16641</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2710/16642</td>
<td>Virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2710/16643</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2710/16644</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2710/16645</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2710/16651</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2710/16652</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2710/16661</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2710/16662</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2710/16663</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2710/16664</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2710/16671</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2710/16688</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2710/16711</td>
<td>Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies</td>
</tr>
<tr>
<td>2710/16721</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2710/16722</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2710/16723</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2710/16731</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2710/16732</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytopytic agent</td>
</tr>
<tr>
<td>2710/16733</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2710/16734</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral</td>
</tr>
<tr>
<td>2710/16741</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2710/16742</td>
<td>Virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2710/16743</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2710/16744</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2710/16745</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2710/16751</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2710/16752</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2710/16761</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2710/16762</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2710/16763</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2710/16764</td>
<td>by serial passage</td>
</tr>
</tbody>
</table>
CPC - 2019.02

2710/16771 . . . Demonstrated in vivo effect
2710/16788 . . . For redistribution
2710/18011 . . . Nimaviridae
2710/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/18023 . . . Virus like particles [VLP]
2710/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/18041 . . . Use of virus, viral particle or viral elements as a vector
2710/18042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/18043 . . . viral genome or elements thereof as genetic vector
2710/18044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/18045 . . . Special targeting system for viral vectors
2710/18051 . . . Methods of production or purification of viral material
2710/18052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/18061 . . . Methods of inactivation or attenuation
2710/18062 . . . by genetic engineering
2710/18063 . . . by chemical treatment
2710/18064 . . . by serial passage
2710/18071 . . . Demonstrated in vivo effect
2710/18088 . . . For redistribution
2710/20011 . . . Papillomaviridae
2710/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/20023 . . . Virus like particles [VLP]
2710/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/20041 . . . Use of virus, viral particle or viral elements as a vector
2710/20042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/20043 . . . viral genome or elements thereof as genetic vector
2710/20044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/20045 . . . Special targeting system for viral vectors
2710/20051 . . . Methods of production or purification of viral material
2710/20052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/20061 . . . Methods of inactivation or attenuation
2710/20062 . . . by genetic engineering
2710/20063 . . . by chemical treatment
2710/20064 . . . by serial passage
2710/20071 . . . Demonstrated in vivo effect
2710/20088 . . . For redistribution
2710/22011 . . . Polyomaviridae, e.g. polyoma, SV40, JC
2710/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/22023 . . . Virus like particles [VLP]
2710/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/22041 . . . Use of virus, viral particle or viral elements as a vector
2710/22042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/22043 . . . viral genome or elements thereof as genetic vector
2710/22044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/22045 . . . Special targeting system for viral vectors
2710/22051 . . . Methods of production or purification of viral material
2710/22052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/22061 . . . Methods of inactivation or attenuation
2710/22062 . . . by genetic engineering
2710/22063 . . . by chemical treatment
2710/22064 . . . by serial passage
2710/22071 . . . Demonstrated in vivo effect
2710/22088 . . . For redistribution
2710/24011 . . . Poxviridae
2710/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/24023 . . . Virus like particles [VLP]
2710/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Orthopoxvirus, e.g. vaccinia virus, variola

Methods of inactivation or attenuation

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Orthopoxvirus, e.g. vaccinia virus, variola

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

dsRNA Viruses (not used)

dsRNA Viruses

Virus like particles [VLP]

For redistribution

Use of virus or viral component as a vector

Use of virus, viral particle or viral elements as a vector

Use of virus or viral particle as vehicle, e.g. encapsulating small organic molecule

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

2720/00021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences

2720/00022 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

2720/00023 . . . . . . Virus like particles [VLP]

2720/00024 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

2720/00025 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2720/00026 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

2720/00027 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. as cytolytic agent

2720/00028 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. disinfectant

2720/00029 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2720/00030 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

2720/00031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

2720/00032 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

2720/00033 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. as cytolytic agent

2720/00034 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. as cytolytic agent

2720/00035 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

2720/00036 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. disinfectant

2720/00037 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2720/00038 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

2720/00039 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. disinfectant

2720/00040 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2720/00041 . . . . . . Use of virus, viral particle or viral elements as a vector

2720/00042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule

2720/00043 . . . . . . viral genome or elements thereof as genetic vector

2720/00044 . . . . . . dsRNA Viruses

2720/00045 . . . . . . Methods of production or purification of viral material

2720/00046 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles

2720/00047 . . . . . . Methods of inactivation or attenuation

2720/00048 . . . . . . by genetic engineering

2720/00049 . . . . . . by chemical treatment

2720/00050 . . . . . . by serial passage

2720/00051 . . . . . . Demonstrated in vivo effect

2720/00052 . . . . . . For redistribution
2720/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/00045 . . . Special targeting system for viral vectors
2720/00051 . . . Methods of production or purification of viral material
2720/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/00061 . . . Methods of inactivation or attenuation
2720/00062 . . . by genetic engineering
2720/00063 . . . by chemical treatment
2720/00064 . . . by serial passage
2720/00071 . . . Demonstrated in vivo effect
2720/00088 . . . For redistribution
2720/10011 . . . Bimaviridae
2720/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/10023 . . . Virus like particles [VLP]
2720/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/10041 . . . Use of virus, viral particle or viral elements as a vectorn
2720/10042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/10043 . . . viral genome or elements thereof as genetic vector
2720/10044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/10045 . . . Special targeting system for viral vectors
2720/10051 . . . Methods of production or purification of viral material
2720/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/10061 . . . Methods of inactivation or attenuation
2720/10062 . . . by genetic engineering
2720/10063 . . . by chemical treatment
2720/10064 . . . by serial passage
2720/10071 . . . Demonstrated in vivo effect
2720/10088 . . . For redistribution
2720/12011 . . . Reoviridae
2720/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12023 . . . Virus like particles [VLP]
2720/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12041 . . . Use of virus, viral particle or viral elements as a vectorn
2720/12042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12043 . . . viral genome or elements thereof as genetic vector
2720/12044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12045 . . . Special targeting system for viral vectors
2720/12051 . . . Methods of production or purification of viral material
2720/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/12061 . . . Methods of inactivation or attenuation
2720/12062 . . . by genetic engineering
2720/12063 . . . by chemical treatment
2720/12064 . . . by serial passage
2720/12071 . . . Demonstrated in vivo effect
2720/12088 . . . For redistribution
2720/12111 . . . Orbivirus, e.g. bluetongue virus
2720/12121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12123 . . . Virus like particles [VLP]
2720/12131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12141 . . . Use of virus, viral particle or viral elements as a vectorn
2720/12142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12143 . . . viral genome or elements thereof as genetic vector
2720/12144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12145 . . . Special targeting system for viral vectors
2720/12151 . . . Methods of production or purification of viral material
2720/12152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/12161 . . . Methods of inactivation or attenuation
2720/12162 . . . by genetic engineering
2720/12163 . . . by chemical treatment
2720/12164 . . . by serial passage
2720/12171 . . . Demonstrated in vivo effect
2720/12188 . . . For redistribution
2720/12211 . . . Orthoreovirus, e.g. mammalian orthoreovirus
2720/12221 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12222 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12223 . . . Virus like particles [VLP]
2720/12231 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12232 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12233 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12234 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12241 . . . Use of virus, viral particle or viral elements as a vector
2720/12242 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12243 . . . viral genome or elements thereof as genetic vector
2720/12244 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12245 . . . Special targeting system for viral vectors
2720/12251 . . . Methods of production or purification of viral material
2720/12252 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/12261 . . . Methods of inactivation or attenuation
2720/12262 . . . by genetic engineering
2720/12263 . . . by chemical treatment
2720/12264 . . . by serial passage
2720/12271 . . . Demonstrated in vivo effect
2720/12288 . . . For redistribution
2720/12311 . . . Rotavirus, e.g. rotavirus A
2720/12321 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12322 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12323 . . . Virus like particles [VLP]
2720/12331 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12332 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12333 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12334 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12341 . . . Use of virus, viral particle or viral elements as a vector
2720/12342 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12343 . . . viral genome or elements thereof as genetic vector
2720/12344 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12345 . . . Special targeting system for viral vectors
2720/12351 . . . Methods of production or purification of viral material
2720/12352 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/12361 . . . Methods of inactivation or attenuation
2720/12362 . . . by genetic engineering
2720/12363 . . . by chemical treatment
2720/12364 . . . by serial passage
2720/12371 . . . Demonstrated in vivo effect
2720/12388 . . . For redistribution

Reverse Transcribing DNA Viruses (not used)

2730/00001 . . . Reverse Transcribing DNA Viruses
2730/00021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2730/00022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2730/00023 . . . Virus like particles [VLP]
2730/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2730/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2730/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2730/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2730/00041 . . . Use of virus, viral particle or viral elements as a vector
2730/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2730/00043 . . . viral genome or elements thereof as genetic vector
2730/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2730/00045 . . . Special targeting system for viral vectors
2730/00051 . . . Methods of production or purification of viral material
2730/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2730/00061 . . . Methods of inactivation or attenuation
2730/00062 . . . by genetic engineering
2730/00063 . . . by chemical treatment
2730/00064 . . . by serial passage
2730/00071 . . . Demonstrated in vivo effect
2730/00088 . . . For redistribution
2730/10011 . . . Hepadnaviridae
2730/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2730/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2730/10023 . . . Virus like particles [VLP]
2730/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Orthohepadnavirus, e.g. hepatitis B virus

For redistribution
effect
Methods of inactivation or attenuation
material
Methods of production or purification of viral
protein
Use of virus, viral particle or viral elements as a
vector
virus or viral particle as vehicle, e.g.
encapsulating small organic molecule
viral genome or elements thereof as genetic
vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
Special targeting system for viral vectors
Methods of production or purification of viral
material
relating to complementing cells and packaging systems for producing virus or viral particles
Methods of inactivation or attenuation
by genetic engineering
by chemical treatment
by serial passage
Demonstrated in vivo effect
For redistribution
Orthohepadnavirus, e.g. hepatitis B virus
Viruses as such, e.g. new isolates, mutants or their genomic sequences
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Virus like particles [VLP]
Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Use of viral protein as therapeutic agent other than vaccine, e.g. as cytolytic agent
Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Use of virus, viral particle or viral elements as a vector
virus or viral particle as vehicle, e.g.
encapsulating small organic molecule
Use of virus, viral particle or viral elements as a vector
viruses other than therapeutic or vaccine, e.g. as cytolytic agent
Use of viral protein as therapeutic agent, other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Use of virus, viral particle or viral elements as a vector
virus or viral particle as vehicle, e.g.
encapsulating small organic molecule
viral genome or elements thereof as genetic
vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
Special targeting system for viral vectors
Methods of production or purification of viral
material
relating to complementing cells and packaging systems for producing virus or viral particles
Methods of inactivation or attenuation
by genetic engineering
by chemical treatment
by serial passage
Demonstrated in vivo effect
For redistribution
Retroviridae
Viruses as such, e.g. new isolates, mutants or their genomic sequences
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Virus like particles [VLP]
Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Use of virus, viral particle or viral elements as a vector
virus or viral particle as vehicle, e.g.
encapsulating small organic molecule
C12N

2740/10043 . . . . . . viral genome or elements thereof as genetic vector
2740/10044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/10045 . . . . . . Special targeting system for viral vectors
2740/10051 . . . . . . Methods of production or purification of viral material
2740/10061 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2740/10062 . . . . . . Methods of inactivation or attenuation
2740/11011 . . . . . . Alpharetrovirus, e.g. avian leucosis virus
2740/11021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/11031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/11032 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/11033 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/11034 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/11041 . . . . . . Use of virus, viral particle or viral elements as a vector
2740/11042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/11043 . . . . . . viral genome or elements thereof as genetic vector
2740/11044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/11045 . . . . . . Special targeting system for viral vectors
2740/11051 . . . . . . Methods of production or purification of viral material
2740/11052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2740/11061 . . . . . . Methods of inactivation or attenuation
2740/11062 . . . . . . by genetic engineering
2740/11063 . . . . . . by chemical treatment
2740/11064 . . . . . . by serial passage
2740/11071 . . . . . . Demonstrated in vivo effect
2740/11088 . . . . . . For redistribution
2740/12011 . . . . . . Betaretrovirus, e.g. mouse mammary tumour virus
2740/12021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/12022 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/12023 . . . . . . Virus like particles [VLP]
2740/12031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/12032 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/12033 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/12034 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/12041 . . . . . . Use of virus, viral particle or viral elements as a vector
2740/12042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/12043 . . . . . . viral genome or elements thereof as genetic vector
2740/12044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/12045 . . . . . . Special targeting system for viral vectors
2740/12051 . . . . . . Methods of production or purification of viral material
2740/12052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2740/12061 . . . . . . Methods of inactivation or attenuation
2740/12062 . . . . . . by genetic engineering
2740/12063 . . . . . . by chemical treatment
2740/12064 . . . . . . by serial passage
2740/12071 . . . . . . Demonstrated in vivo effect
2740/12088 . . . . . . For redistribution
2740/13011 . . . . . . Gammatretrovirus, e.g. murine leukemia virus
2740/13021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/13022 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/13023 . . . . . . Virus like particles [VLP]
2740/13031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/13032 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/13033 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/13034 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/13041 . . . . . . Use of virus, viral particle or viral elements as a vector
2740/13042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/13043 . . . . . . viral genome or elements thereof as genetic vector
2740/13044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/13045 . . . . . . Special targeting system for viral vectors
2740/13051 . . . . . . Methods of production or purification of viral material
2740/13052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2740/13061 . . . . . . Methods of inactivation or attenuation
Lentivirus, not HIV, e.g. FIV, SIV

Deltaretrovirus, e.g. bovine leukeamia virus

as a vector

viral protein
e.g. live-attenuated or inactivated virus, VLP,

Use of virus or viral component as vaccine,
other than vaccine, e.g. apoptosis inducing or
vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent, other than
vaccine, e.g. disinfectant

Uses of virus other than therapeutic or
vaccine, e.g. apoptosis inducing or
vaccine, e.g. as cytolytic agent

Virus like particles [VLP]

viral genome or elements thereof as
structural or functional aspects of known
viral proteins or genes

New viral proteins or individual genes, new
structural or functional aspects of known
viral proteins or genes

Use of virus or viral component as vaccine,
e.g. live-attenuated or inactivated virus, VLP,
viral protein

Use of virus, viral particle or viral elements
as a vector

virus or viral particle as vehicle, e.g.
encapsulating small organic molecule

viral genome or elements thereof as
viral particle

Chimeric viral vector comprising
heterologous viral elements for production
of another viral vector

Special targeting system for viral vectors

Methods of production or purification of
viral material

relating to complementing cells and
packaging systems for producing virus or
viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or
vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than
vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent
other than vaccine, e.g. apoptosis inducing or
anti-inflammatory

Use of virus or viral component as vaccine,
e.g. live-attenuated or inactivated virus, VLP,
viral protein

Use of virus, viral particle or viral elements
as a vector

virus or viral particle as vehicle, e.g.
encapsulating small organic molecule

Chimeric viral vector comprising
heterologous viral elements for production
of another viral vector

Special targeting system for viral vectors

Methods of production or purification of
viral material

relating to complementing cells and
packaging systems for producing virus or
viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or
vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than
vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent
other than vaccine, e.g. apoptosis inducing or
anti-inflammatory

Use of virus or viral component as vaccine,
e.g. live-attenuated or inactivated virus, VLP,
viral protein

Use of virus, viral particle or viral elements
as a vector

virus or viral particle as vehicle, e.g.
encapsulating small organic molecule

Chimeric viral vector comprising
heterologous viral elements for production
of another viral vector

Special targeting system for viral vectors

Methods of production or purification of
viral material

relating to complementing cells and
packaging systems for producing virus or
viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or
vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than
vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent
other than vaccine, e.g. apoptosis inducing or
anti-inflammatory

Use of virus or viral component as vaccine,
e.g. live-attenuated or inactivated virus, VLP,
viral protein

Use of virus, viral particle or viral elements
as a vector

virus or viral particle as vehicle, e.g.
encapsulating small organic molecule

Chimeric viral vector comprising
heterologous viral elements for production
of another viral vector

Special targeting system for viral vectors

Methods of production or purification of
viral material

relating to complementing cells and
packaging systems for producing virus or
viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or
vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than
vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent
other than vaccine, e.g. apoptosis inducing or
anti-inflammatory

Use of virus or viral component as vaccine,
e.g. live-attenuated or inactivated virus, VLP,
viral protein

Use of virus, viral particle or viral elements
as a vector

virus or viral particle as vehicle, e.g.
encapsulating small organic molecule

Chimeric viral vector comprising
heterologous viral elements for production
of another viral vector

Special targeting system for viral vectors

Methods of production or purification of
viral material

relating to complementing cells and
packaging systems for producing virus or
viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or
vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than
vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent
other than vaccine, e.g. apoptosis inducing or
anti-inflammatory

Use of virus or viral component as vaccine,
e.g. live-attenuated or inactivated virus, VLP,
viral protein

Use of virus, viral particle or viral elements
as a vector

virus or viral particle as vehicle, e.g.
encapsulating small organic molecule

Chimeric viral vector comprising
heterologous viral elements for production
of another viral vector

Special targeting system for viral vectors

Methods of production or purification of
viral material

relating to complementing cells and
packaging systems for producing virus or
viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or
vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than
vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent
other than vaccine, e.g. apoptosis inducing or
anti-inflammatory

Use of virus or viral component as vaccine,
e.g. live-attenuated or inactivated virus, VLP,
viral protein

Use of virus, viral particle or viral elements
as a vector

virus or viral particle as vehicle, e.g.
encapsulating small organic molecule

Chimeric viral vector comprising
heterologous viral elements for production
of another viral vector

Special targeting system for viral vectors

Methods of production or purification of
viral material

relating to complementing cells and
packaging systems for producing virus or
viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or
vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than
vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent
other than vaccine, e.g. apoptosis inducing or
anti-inflammatory

Use of virus or viral component as vaccine,
e.g. live-attenuated or inactivated virus, VLP,
viral protein

Use of virus, viral particle or viral elements
as a vector

virus or viral particle as vehicle, e.g.
encapsulating small organic molecule

Chimeric viral vector comprising
heterologous viral elements for production
of another viral vector

Special targeting system for viral vectors

Methods of production or purification of
viral material

relating to complementing cells and
packaging systems for producing virus or
viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or
vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than
vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent
other than vaccine, e.g. apoptosis inducing or
anti-inflammatory

Use of virus or viral component as vaccine,
e.g. live-attenuated or inactivated virus, VLP,
viral protein

Use of virus, viral particle or viral elements
as a vector

virus or viral particle as vehicle, e.g.
encapsulating small organic molecule

Chimeric viral vector comprising
heterologous viral elements for production
of another viral vector

Special targeting system for viral vectors

Methods of production or purification of
viral material

relating to complementing cells and
packaging systems for producing virus or
viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or
vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than
vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent
other than vaccine, e.g. apoptosis inducing or
anti-inflammatory

Use of virus or viral component as vaccine,
e.g. live-attenuated or inactivated virus, VLP,
viral protein

Use of virus, viral particle or viral elements
as a vector

virus or viral particle as vehicle, e.g.
encapsulating small organic molecule

Chimeric viral vector comprising
heterologous viral elements for production
of another viral vector

Special targeting system for viral vectors

Methods of production or purification of
viral material

relating to complementing cells and
packaging systems for producing virus or
viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or
vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than
vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent
other than vaccine, e.g. apoptosis inducing or
anti-inflammatory

Use of virus or viral component as vaccine,
e.g. live-attenuated or inactivated virus, VLP,
viral protein

Use of virus, viral particle or viral elements
as a vector

virus or viral particle as vehicle, e.g.
encapsulating small organic molecule
2740/16211 . . . . concerning HIV gagpol
2740/16222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16271 . . . . Demonstrated in vivo effect
2740/16288 . . . . For redistribution
2740/16311 . . . . concerning HIV regulatory proteins
2740/16322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16371 . . . . Demonstrated in vivo effect
2740/16388 . . . . For redistribution
2740/17011 . . . . Spumavirus, e.g. chimpanzee foamy virus
2740/17021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/17022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/17023 . . . . Virus like particles [VLP]
2740/17031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/17032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/17033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/17034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/17041 . . . . Use of virus, viral particle or viral elements as a vector
2740/17042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/17043 . . . . viral genome or elements thereof as genetic vector
2740/17044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/17045 . . . . Special targeting system for viral vectors
2740/17051 . . . . Methods of production or purification of viral material
2740/17052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2740/17061 . . . . Methods of inactivation or attenuation
2740/17062 . . . . by genetic engineering
2740/17063 . . . . by chemical treatment
2740/17064 . . . . by serial passage
2740/17071 . . . . Demonstrated in vivo effect
2740/17088 . . . . For redistribution
2750/00 . . . ssDNA Viruses (not used)
2750/00011 . . . ssDNA Viruses
2750/00021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/00022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/00023 . . . Virus like particles [VLP]
2750/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/00041 . . . Use of virus, viral particle or viral elements as a vector
2750/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/00043 . . . viral genome or elements thereof as genetic vector
2750/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/00045 . . . Special targeting system for viral vectors
2750/00051 . . . Methods of production or purification of viral material
2750/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/00061 . . . Methods of inactivation or attenuation
2750/00062 . . . by genetic engineering
2750/00063 . . . by chemical treatment
2750/00064 . . . by serial passage
2750/00071 . . . Demonstrated in vivo effect
2750/00088 . . . For redistribution
2750/10011 . . . Circoviridae
2750/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/10023 . . . Virus like particles [VLP]
2750/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/10041 . . . Use of virus, viral particle or viral elements as a vector
2750/10042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/10043 . . . viral genome or elements thereof as genetic vector
2750/10044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/10045 . . . Special targeting system for viral vectors
2750/10051 . . . Methods of production or purification of viral material
2750/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/10061 . . . Methods of inactivation or attenuation
C12N

2750/10062 . . . by genetic engineering
2750/10063 . . . by chemical treatment
2750/10064 . . . by serial passage
2750/10071 . . . Demonstrated in vivo effect
2750/10088 . . . For redistribution
2750/12011 . . . Geminiviridae
2750/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/12023 . . . Virus like particles [VLP]
2750/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/12041 . . . Use of virus, viral particle or viral elements as a vector
2750/12042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/12043 . . . viral genome or elements thereof as genetic vector
2750/12044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/12045 . . . Special targeting system for viral vectors
2750/12051 . . . Methods of production or purification of viral material
2750/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/12061 . . . Methods of inactivation or attenuation
2750/12062 . . . by genetic engineering
2750/12063 . . . by chemical treatment
2750/12064 . . . by serial passage
2750/12071 . . . Demonstrated in vivo effect
2750/12088 . . . For redistribution
2750/14043 . . . viral genome or elements thereof as genetic vector
2750/14044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/14045 . . . Special targeting system for viral vectors
2750/14051 . . . Methods of production or purification of viral material
2750/14052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/14061 . . . Methods of inactivation or attenuation
2750/14062 . . . by genetic engineering
2750/14063 . . . by chemical treatment
2750/14064 . . . by serial passage
2750/14071 . . . Demonstrated in vivo effect
2750/14088 . . . For redistribution
2750/14111 . . . Dependovirus, e.g. adenovassociated viruses
2750/14121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/14122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/14123 . . . Virus like particles [VLP]
2750/14131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/14132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/14133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/14134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/14141 . . . Use of virus, viral particle or viral elements as a vector
2750/14142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/14143 . . . viral genome or elements thereof as genetic vector
2750/14144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/14145 . . . Special targeting system for viral vectors
2750/14151 . . . Methods of production or purification of viral material
2750/14152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/14161 . . . Methods of inactivation or attenuation
2750/14162 . . . by genetic engineering
2750/14163 . . . by chemical treatment
2750/14164 . . . by serial passage
2750/14171 . . . Demonstrated in vivo effect
2750/14188 . . . For redistribution
2750/14211 . . . Erythrovirus, e.g. B19 virus
2750/14221 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/14222 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/14223 . . . Virus like particles [VLP]
2750/14231 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Methods of inactivation or attenuation

Methods of production or purification of viral material

Use of virus, viral particle or viral elements as a vector

Use of virus or viral particle as vehicle, e.g.

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Parvovirus, e.g. minute virus of mice

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. apoptosis inducing or anti-inflammatory

Viruses like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2760/10043</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2760/10044</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2760/10045</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2760/10051</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2760/10052</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2760/10061</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2760/10062</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2760/10063</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2760/10064</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2760/10071</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2760/10088</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2760/10111</td>
<td>Deltavirus, e.g. hepatitis delta virus</td>
</tr>
<tr>
<td>2760/10121</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2760/10122</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2760/10123</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2760/10131</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2760/10132</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2760/10133</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2760/10134</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2760/10141</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2760/10142</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2760/10143</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2760/10144</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2760/10145</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2760/10151</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2760/10152</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2760/10161</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2760/10162</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2760/10163</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2760/10164</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2760/10171</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2760/10188</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2760/12011</td>
<td>Bunyaviridae</td>
</tr>
<tr>
<td>2760/12021</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2760/12022</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2760/12023</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2760/12031</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2760/12032</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2760/12033</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2760/12034</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2760/12041</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2760/12042</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2760/12043</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2760/12044</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2760/12045</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2760/12051</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2760/12052</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2760/12061</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2760/12062</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2760/12063</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2760/12064</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2760/12071</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2760/12088</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2760/12111</td>
<td>Hantavirus, e.g. Hantaan virus</td>
</tr>
<tr>
<td>2760/12121</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2760/12122</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2760/12123</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2760/12131</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2760/12132</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2760/12133</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2760/12134</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2760/12141</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2760/12142</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2760/12143</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2760/12144</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2760/12145</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2760/12151</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2760/12152</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2760/12161</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2760/12162</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2760/12163</td>
<td>by chemical treatment</td>
</tr>
</tbody>
</table>
Virus like particles [VLP]

Viral proteins or genes

Structural or functional aspects of known viral proteins or genes

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Filoviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Marburgvirus, e.g. Lake Victoria marburgvirus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viral genome or elements thereof as genetic vector
C12N

2760/14232 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/14233 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/14234 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/14241 . . . Use of virus, viral particle or viral elements as a vector
2760/14242 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/14243 . . . viral genome or elements thereof as genetic vector
2760/14244 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/14245 . . . Special targeting system for viral vectors
2760/14251 . . . Methods of production or purification of viral material
2760/14252 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/14261 . . . Methods of inactivation or attenuation
2760/14262 . . . by genetic engineering
2760/14263 . . . by chemical treatment
2760/14264 . . . by serial passage
2760/14271 . . . Demonstrated in vivo effect
2760/14288 . . . For redistribution
2760/16011 . . . Orthomyxoviridae
2760/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/16023 . . . Virus like particles [VLP]
2760/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/16041 . . . Use of virus, viral particle or viral elements as a vector
2760/16042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/16043 . . . viral genome or elements thereof as genetic vector
2760/16044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/16045 . . . Special targeting system for viral vectors
2760/16051 . . . Methods of production or purification of viral material
2760/16052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/16061 . . . Methods of inactivation or attenuation
2760/16062 . . . by genetic engineering
2760/16063 . . . by chemical treatment
2760/16064 . . . by serial passage
2760/16071 . . . Demonstrated in vivo effect
2760/16088 . . . For redistribution
2760/16111 . . . Influenzavirus A, i.e. influenza A virus
2760/16121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/16122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/16123 . . . Virus like particles [VLP]
2760/16131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/16132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/16133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/16134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/16141 . . . Use of virus, viral particle or viral elements as a vector
2760/16142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/16143 . . . viral genome or elements thereof as genetic vector
2760/16144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/16145 . . . Special targeting system for viral vectors
2760/16151 . . . Methods of production or purification of viral material
2760/16152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/16161 . . . Methods of inactivation or attenuation
2760/16162 . . . by genetic engineering
2760/16163 . . . by chemical treatment
2760/16164 . . . by serial passage
2760/16171 . . . Demonstrated in vivo effect
2760/16188 . . . For redistribution
2760/16211 . . . Influenzavirus B, i.e. influenza B virus
2760/16221 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/16222 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/16223 . . . Virus like particles [VLP]
2760/16231 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/16232 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/16233 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/16234 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/16241 . . . Use of virus, viral particle or viral elements as a vector
2760/16242 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/16243 . . . viral genome or elements thereof as genetic vector
2760/16244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/16245 . . . . . Special targeting system for viral vectors
2760/16251 . . . . . Methods of production or purification of viral material
2760/16252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/16261 . . . . . Methods of inactivation or attenuation
2760/16262 . . . . . by genetic engineering
2760/16263 . . . . . by chemical treatment
2760/16264 . . . . . by serial passage
2760/16271 . . . . . Demonstrated in vivo effect
2760/16288 . . . . . For redistribution
2760/16311 . . . . . Influenzavirus C, i.e. influenza C virus
2760/16321 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/16322 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/16323 . . . . . Virus like particles [VLP]
2760/16331 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/16332 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/16333 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/16334 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/16341 . . . . . Use of virus, viral particle or viral elements as a vector
2760/16342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/16343 . . . . . viral genome or elements thereof as genetic vector
2760/16344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/16345 . . . . . Special targeting system for viral vectors
2760/16351 . . . . . Methods of production or purification of viral material
2760/16352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/16361 . . . . . Methods of inactivation or attenuation
2760/16362 . . . . . by genetic engineering
2760/16363 . . . . . by chemical treatment
2760/16364 . . . . . by serial passage
2760/16371 . . . . . Demonstrated in vivo effect
2760/16388 . . . . . For redistribution
2760/18011 . . . . . Paramyxoviridae
2760/18021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/18022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/18023 . . . . . Virus like particles [VLP]
2760/18031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/18032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/18033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18041 . . . . . Use of virus, viral particle or viral elements as a vector
2760/18042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18043 . . . . . viral genome or elements thereof as genetic vector
2760/18044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18045 . . . . . Special targeting system for viral vectors
2760/18051 . . . . . Methods of production or purification of viral material
2760/18052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/18061 . . . . . Methods of inactivation or attenuation
2760/18062 . . . . . by genetic engineering
2760/18063 . . . . . by chemical treatment
2760/18064 . . . . . by serial passage
2760/18071 . . . . . Demonstrated in vivo effect
2760/18088 . . . . . For redistribution
2760/18111 . . . . . Avulavirus, e.g. Newcastle disease virus
2760/18121 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/18122 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/18123 . . . . . Virus like particles [VLP]
2760/18131 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/18132 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/18133 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18134 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18141 . . . . . Use of virus, viral particle or viral elements as a vector
2760/18142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18143 . . . . . viral genome or elements thereof as genetic vector
2760/18144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18145 . . . . . Special targeting system for viral vectors
2760/18151 . . . . . Methods of production or purification of viral material
2760/18152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/18161 . . . . . Methods of inactivation or attenuation
2760/18162 . . . . . by genetic engineering
2760/18163 . . . . . by chemical treatment
2760/18164 . . . . . by serial passage
2760/18171 . . . . . Demonstrated in vivo effect
For redistribution

Henipavirus, e.g. hendra virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Metapneumovirus, e.g. avian pneumovirus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Pneumovirus, e.g. human respiratory syncytial virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Methods of inactivation or attenuation of viral material

Methods of production or purification of viral material

Use of virus, viral particle or viral elements as a vector

Methods of inactivation or attenuation of virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Respirovirus, e.g. Bovine, human parainfluenza 1,3

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses as such, e.g. live-attenuated or inactivated virus, VLP, viral protein

Viruses as such, e.g. live-attenuated or inactivated virus, VLP, viral protein

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. as a vector

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Sendai virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses as such, e.g. live-attenuated or inactivated virus, VLP, viral protein

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. as a vector

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Sendai virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses as such, e.g. live-attenuated or inactivated virus, VLP, viral protein
<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2760/18843</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2760/18845</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2760/18851</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2760/18852</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2760/18861</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2760/18862</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2760/18863</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2760/18864</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2760/18871</td>
<td>Demonstrated <em>in vivo</em> effect</td>
</tr>
<tr>
<td>2760/18888</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2760/20011</td>
<td>Rhabdoviridae</td>
</tr>
<tr>
<td>2760/20021</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2760/20022</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2760/20023</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2760/20031</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2760/20032</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2760/20033</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2760/20034</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2760/20041</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2760/20042</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2760/20043</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2760/20044</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2760/20045</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2760/20051</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2760/20052</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2760/20061</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2760/20062</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2760/20063</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2760/20064</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2760/20071</td>
<td>Demonstrated <em>in vivo</em> effect</td>
</tr>
<tr>
<td>2760/20088</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2760/20111</td>
<td>Lyssavirus, e.g. rabies virus</td>
</tr>
<tr>
<td>2760/20121</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2760/20122</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2760/20123</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2760/20131</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2760/20132</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2760/20133</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2760/20134</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2760/20141</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2760/20142</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2760/20143</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2760/20144</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2760/20145</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2760/20151</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2760/20152</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2760/20161</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2760/20162</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2760/20163</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2760/20164</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2760/20171</td>
<td>Demonstrated <em>in vivo</em> effect</td>
</tr>
<tr>
<td>2760/20188</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2760/20211</td>
<td>Vesiculovirus, e.g. vesicular stomatitis Indiana virus</td>
</tr>
<tr>
<td>2760/20221</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2760/20222</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2760/20223</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2760/20231</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2760/20232</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2760/20233</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2760/20234</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2760/20241</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2760/20242</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2760/20243</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2760/20244</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2760/20245</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2760/20251</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2760/20252</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
</tbody>
</table>
ssRNA Viruses positive-sense

- Virus like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Use of virus, viral particle or viral elements as a vector
- Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- Viral genome or elements thereof as genetic vector
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Special targeting system for viral vectors
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- Methods of inactivation or attenuation
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- For redistribution

Arteriviridae

- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Viruses like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- For redistribution

Astroviridae

- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Viruses like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- For redistribution

Bromoviridae

- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Viruses like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- For redistribution

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

For redistribution

Methods of inactivation or attenuation

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

For redistribution

Methods of inactivation or attenuation

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

For redistribution

Methods of inactivation or attenuation

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

For redistribution
Methods of inactivation or attenuation of material

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Caliciviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

viral genome or elements thereof as genetic vector

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Coronaviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

viral genome or elements thereof as genetic vector

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Comoviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus or viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Use of virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Special targeting system for viral vectors

another viral vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus or viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Viral genome or elements thereof as genetic vector

December 2021
<table>
<thead>
<tr>
<th>CPC Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2770/20044</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2770/20045</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2770/20051</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2770/20052</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2770/20061</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2770/20062</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2770/20063</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2770/20064</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2770/20071</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2770/20088</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2770/22011</td>
<td>Flaviviridae</td>
</tr>
<tr>
<td>2770/22021</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2770/22022</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2770/22023</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2770/22031</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2770/22032</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2770/22033</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2770/22034</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2770/22041</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2770/22042</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2770/22043</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2770/22044</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2770/22045</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2770/22051</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2770/22052</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2770/22061</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2770/22062</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2770/22063</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2770/22064</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2770/22071</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2770/22088</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2770/24011</td>
<td>Flavivirus, e.g. yellow fever virus, dengue, JEV</td>
</tr>
<tr>
<td>2770/24021</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2770/24022</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2770/24023</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2770/24031</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2770/24032</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2770/24033</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2770/24034</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2770/24041</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2770/24042</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2770/24043</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2770/24044</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2770/24045</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2770/24051</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2770/24052</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2770/24061</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2770/24062</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2770/24063</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2770/24064</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2770/24071</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2770/24088</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2770/24111</td>
<td>Expression vector, e.g. as a vector</td>
</tr>
<tr>
<td>2770/24121</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2770/24122</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2770/24123</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2770/24131</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2770/24132</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2770/24133</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2770/24134</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2770/24141</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2770/24142</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2770/24143</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2770/24144</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2770/24145</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2770/24151</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2770/24152</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2770/24161</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2770/24162</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2770/24163</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2770/24164</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2770/24171</td>
<td>Demonstrated in vivo effect</td>
</tr>
</tbody>
</table>
2770/24188 . . . . For redistribution  
2770/24211 . . . . Hepacivirus, e.g. hepatitis C virus, hepatitis G virus  
2770/24221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences  
2770/24222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes  
2770/24223 . . . . Virus like particles [VLP]  
2770/24231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant  
2770/24232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent  
2770/24233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory  
2770/24234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein  
2770/24241 . . . . Use of virus, viral particle or viral elements as a vector  
2770/24242 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule  
2770/24243 . . . . viral genome or elements thereof as genetic vector  
2770/24244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector  
2770/24245 . . . . Special targeting system for viral vectors  
2770/24251 . . . . Methods of production or purification of viral material  
2770/24252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles  
2770/24261 . . . . Methods of inactivation or attenuation  
2770/24262 . . . . by genetic engineering  
2770/24263 . . . . by chemical treatment  
2770/24264 . . . . by serial passage  
2770/24271 . . . . Demonstrated in vivo effect  
2770/24288 . . . . For redistribution  
2770/24311 . . . . Pestivirus, e.g. bovine viral diarrhea virus  
2770/24321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences  
2770/24322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes  
2770/24323 . . . . Virus like particles [VLP]  
2770/24331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant  
2770/24332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent  
2770/24333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory  
2770/24334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein  
2770/24341 . . . . Use of virus, viral particle or viral elements as a vector  
2770/24342 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule  
2770/24343 . . . . viral genome or elements thereof as genetic vector  
2770/24344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector  
2770/24345 . . . . Special targeting system for viral vectors  
2770/24351 . . . . Methods of production or purification of viral material  
2770/24352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles  
2770/24361 . . . . Methods of inactivation or attenuation  
2770/24362 . . . . by genetic engineering  
2770/24363 . . . . by chemical treatment  
2770/24364 . . . . by serial passage  
2770/24371 . . . . Demonstrated in vivo effect  
2770/24388 . . . . For redistribution  
2770/26011 . . . . Flexiviridae  
2770/26021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences  
2770/26022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes  
2770/26023 . . . . Virus like particles [VLP]  
2770/26031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant  
2770/26032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent  
2770/26033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory  
2770/26034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein  
2770/26041 . . . . Use of virus, viral particle or viral elements as a vector  
2770/26042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule  
2770/26043 . . . . viral genome or elements thereof as genetic vector  
2770/26044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector  
2770/26045 . . . . Special targeting system for viral vectors  
2770/26051 . . . . Methods of production or purification of viral material  
2770/26052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles  
2770/26061 . . . . Methods of inactivation or attenuation  
2770/26062 . . . . by genetic engineering  
2770/26063 . . . . by chemical treatment  
2770/26064 . . . . by serial passage  
2770/26071 . . . . Demonstrated in vivo effect  
2770/26088 . . . . For redistribution  
2770/28021 . . . . Hepeviridae  
2770/28022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes  
2770/28023 . . . . Virus like particles [VLP]  
2770/28031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant  
2770/28032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N

2770/28033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/28034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/28041 . . . Use of virus, viral particle or viral elements as a vector
2770/28042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/28043 . . . viral genome or elements thereof as genetic vector
2770/28044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/28045 . . . Special targeting system for viral vectors
2770/28051 . . . Methods of production or purification of viral material
2770/28052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/28061 . . . Methods of inactivation or attenuation
2770/28062 . . . by genetic engineering
2770/28063 . . . by chemical treatment
2770/28064 . . . by serial passage
2770/28071 . . . Demonstrated in vivo effect
2770/28088 . . . For redistribution
2770/28111 . . . Hepevirus, e.g. hepatitis E virus
2770/28121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/28122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/28123 . . . Virus like particles [VLP]
2770/28131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/28132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/28133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/28134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/28141 . . . Use of virus, viral particle or viral elements as a vector
2770/28142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/28143 . . . viral genome or elements thereof as genetic vector
2770/28144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/28145 . . . Special targeting system for viral vectors
2770/28151 . . . Methods of production or purification of viral material
2770/28152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/28161 . . . Methods of inactivation or attenuation
2770/28162 . . . by genetic engineering
2770/28163 . . . by chemical treatment
2770/28164 . . . by serial passage
2770/28171 . . . Demonstrated in vivo effect
2770/28188 . . . . . . For redistribution
2770/30011 . . . Nodaviridae
2770/30021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/30022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/30023 . . . Virus like particles [VLP]
2770/30031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/30032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/30033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/30034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/30041 . . . Use of virus, viral particle or viral elements as a vector
2770/30042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/30043 . . . viral genome or elements thereof as genetic vector
2770/30044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/30045 . . . Special targeting system for viral vectors
2770/30051 . . . Methods of production or purification of viral material
2770/30052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/30061 . . . Methods of inactivation or attenuation
2770/30062 . . . by genetic engineering
2770/30063 . . . by chemical treatment
2770/30064 . . . by serial passage
2770/30071 . . . Demonstrated in vivo effect
2770/30088 . . . For redistribution
2770/32011 . . . Picornaviridae
2770/32021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32023 . . . Virus like particles [VLP]
2770/32031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32041 . . . Use of virus, viral particle or viral elements as a vector
2770/32042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32043 . . . viral genome or elements thereof as genetic vector
C12N

2770/32044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32045 . . . . Special targeting system for viral vectors
2770/32051 . . . . Methods of production or purification of viral material
2770/32052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32061 . . . . Methods of inactivation or attenuation
2770/32062 . . . . by genetic engineering
2770/32063 . . . . by chemical treatment
2770/32064 . . . . by serial passage
2770/32071 . . . . Demonstrated in vivo effect
2770/32088 . . . . For redistribution
2770/32111 . . . . Aphthovirus, e.g. footandmouth disease virus
2770/32121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32123 . . . . Virus like particles [VLP]
2770/32131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32141 . . . . Use of virus, viral particle or viral elements as a vector
2770/32142 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32143 . . . . viral genome or elements thereof as genetic vector
2770/32144 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32145 . . . . Special targeting system for viral vectors
2770/32151 . . . . Methods of production or purification of viral material
2770/32152 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32161 . . . . Methods of inactivation or attenuation
2770/32162 . . . . by genetic engineering
2770/32163 . . . . by chemical treatment
2770/32164 . . . . by serial passage
2770/32171 . . . . Demonstrated in vivo effect
2770/32188 . . . . For redistribution
2770/32211 . . . . Cardiovirus, e.g. encephalomyocarditis virus
2770/32221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32223 . . . . Virus like particles [VLP]
2770/32231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32241 . . . . Use of virus, viral particle or viral elements as a vector
2770/32242 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32243 . . . . viral genome or elements thereof as genetic vector
2770/32244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32245 . . . . Special targeting system for viral vectors
2770/32251 . . . . Methods of production or purification of viral material
2770/32252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32261 . . . . Methods of inactivation or attenuation
2770/32262 . . . . by genetic engineering
2770/32263 . . . . by chemical treatment
2770/32264 . . . . by serial passage
2770/32271 . . . . Demonstrated in vivo effect
2770/32288 . . . . For redistribution
2770/32311 . . . . Enterovirus
2770/32321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32323 . . . . Virus like particles [VLP]
2770/32331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32341 . . . . Use of virus, viral particle or viral elements as a vector
2770/32342 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32343 . . . . viral genome or elements thereof as genetic vector
2770/32344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32345 . . . . Special targeting system for viral vectors
2770/32351 . . . . Methods of production or purification of viral material
2770/32352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32361 . . . . Methods of inactivation or attenuation
2770/32362 . . . . by genetic engineering
2770/32363 . . . . by chemical treatment
2770/32364 . . . . by serial passage
2770/32371 . . . . Demonstrated in vivo effect
For redistribution

Hepatovirus, i.e. hepatitis A virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Use of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Methods of production or purification of viral material

Relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

Methods of production or purification of viral vectors

Methods of inactivation or attenuation

Methods of production or purification of viral vectors

Methods of inactivation or attenuation

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral vectors

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral vectors

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Demonstrated in vivo effect

For redistribution

Poliovirus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

For redistribution

Parechovirus, e.g. human parechovirus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Use of virus other than therapeutic or vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]

Virus like particles [VLP]
C12N

2770/32733 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32734 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32741 . . . Use of virus, viral particle or viral elements as a vector
2770/32742 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32743 . . . viral genome or elements thereof as genetic vector
2770/32744 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32745 . . . Special targeting system for viral vectors
2770/32751 . . . Methods of production or purification of viral material
2770/32752 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32761 . . . Methods of inactivation or attenuation
2770/32762 . . . by genetic engineering
2770/32763 . . . by chemical treatment
2770/32764 . . . by serial passage
2770/32771 . . . Demonstrated in vivo effect
2770/32788 . . . For redistribution
2770/34011 . . . Potyviridae
2770/34021 . . . Viruses such as, e.g. new isolates, mutants or their genomic sequences
2770/34022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/34023 . . . Virus like particles [VLP]
2770/34031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/34032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/34033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/34034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/34041 . . . Use of virus, viral particle or viral elements as a vector
2770/34042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/34043 . . . viral genome or elements thereof as genetic vector
2770/34044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/34045 . . . Special targeting system for viral vectors
2770/34051 . . . Methods of production or purification of viral material
2770/34052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/34061 . . . Methods of inactivation or attenuation
2770/34062 . . . by genetic engineering
2770/34063 . . . by chemical treatment
2770/34064 . . . by serial passage
2770/34071 . . . Demonstrated in vivo effect
2770/34088 . . . For redistribution
2770/36011 . . . Togaviridae
2770/36021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/36022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/36023 . . . Virus like particles [VLP]
2770/36031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/36032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/36033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/36034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/36041 . . . Use of virus, viral particle or viral elements as a vector
2770/36042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/36043 . . . viral genome or elements thereof as genetic vector
2770/36044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/36045 . . . Special targeting system for viral vectors
2770/36051 . . . Methods of production or purification of viral material
2770/36052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/36061 . . . Methods of inactivation or attenuation
2770/36062 . . . by genetic engineering
2770/36063 . . . by chemical treatment
2770/36064 . . . by serial passage
2770/36071 . . . Demonstrated in vivo effect
2770/36088 . . . For redistribution
2770/36111 . . . Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semiliki
2770/36121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/36122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/36123 . . . Virus like particles [VLP]
2770/36131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/36132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/36133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/36134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/36141 . . . Use of virus, viral particle or viral elements as a vector
2770/36142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/36143 . . . viral genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of inactivation or attenuation
- by serial passage
- by chemical treatment
- by genetic engineering

Viral genome or elements thereof as genetic vector

Special targeting system for viral vectors

Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- as vector

Viruses as such, e.g. new isolates, mutants or their genomic sequences

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of inactivation or attenuation
- by serial passage
- by chemical treatment
- by genetic engineering

Viral genome or elements thereof as genetic vector

Special targeting system for viral vectors

Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- as vector

Viruses as such, e.g. new isolates, mutants or their genomic sequences

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of inactivation or attenuation
- by serial passage
- by chemical treatment
- by genetic engineering

Viral genome or elements thereof as genetic vector

Special targeting system for viral vectors

Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- as vector

Viruses as such, e.g. new isolates, mutants or their genomic sequences

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of inactivation or attenuation
- by serial passage
- by chemical treatment
- by genetic engineering

Viral genome or elements thereof as genetic vector

Special targeting system for viral vectors

Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- as vector

Viruses as such, e.g. new isolates, mutants or their genomic sequences

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of inactivation or attenuation
- by serial passage
- by chemical treatment
- by genetic engineering

Viral genome or elements thereof as genetic vector

Special targeting system for viral vectors

Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- as vector

Viruses as such, e.g. new isolates, mutants or their genomic sequences

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of inactivation or attenuation
- by serial passage
- by chemical treatment
- by genetic engineering

Viral genome or elements thereof as genetic vector

Special targeting system for viral vectors
Naked RNA Viruses (not used)

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolitic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Narnaviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolitic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Prions

Viroids and subviral agents (not used)

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolitic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Prions

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2790/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2790/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2790/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2790/10041 . . . Use of virus, viral particle or viral elements as a vector
2790/10042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2790/10043 . . . viral genome or elements thereof as genetic vector
2790/10044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2790/10045 . . . Special targeting system for viral vectors
2790/10051 . . . Methods of production or purification of viral material
2790/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2790/10061 . . . Methods of inactivation or attenuation
2790/10062 . . . by genetic engineering
2790/10063 . . . by chemical treatment
2790/10064 . . . by serial passage
2790/10071 . . . Demonstrated in vivo effect
2790/10088 . . . For redistribution
2790/12011 . . . Satellite viruses
2790/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2790/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2790/12023 . . . Virus like particles [VLP]
2790/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2790/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2790/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2790/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2790/12041 . . . Use of virus, viral particle or viral elements as a vector
2790/12042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2790/12043 . . . viral genome or elements thereof as genetic vector
2790/12044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2790/12045 . . . Special targeting system for viral vectors
2790/12051 . . . Methods of production or purification of viral material
2790/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2790/12061 . . . Methods of inactivation or attenuation
2790/12062 . . . by genetic engineering
2790/12063 . . . by chemical treatment
2790/12064 . . . by serial passage
2790/12071 . . . Demonstrated in vivo effect
2790/12088 . . . For redistribution
2790/14011 . . . Viroids
2790/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2790/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2790/14023 . . . Virus like particles [VLP]
2790/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2790/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2790/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2790/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2790/14041 . . . Use of virus, viral particle or viral elements as a vector
2790/14042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2790/14043 . . . viral genome or elements thereof as genetic vector
2790/14044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2790/14045 . . . Special targeting system for viral vectors
2790/14051 . . . Methods of production or purification of viral material
2790/14052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2790/14061 . . . Methods of inactivation or attenuation
2790/14062 . . . by genetic engineering
2790/14063 . . . by chemical treatment
2790/14064 . . . by serial passage
2790/14071 . . . Demonstrated in vivo effect
2790/14088 . . . For redistribution
2792/00 Archaeabacteria viruses (not used)
2792/00011 . . . Archaeabacteria viruses
2792/00021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2792/00022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2792/00023 . . . Virus like particles [VLP]
2792/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2792/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2792/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2792/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2792/00041 . . . Use of virus, viral particle or viral elements as a vector
2792/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
**Bacteriophages (not used)**

- **2795/0001** . . . Bacteriophages
- **2795/0002** . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- **2795/0003** . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- **2795/0004** . . . Virus like particles [VLP]
- **2795/0005** . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- **2795/0006** . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- **2795/0007** . . . Use of virus, viral particle or viral elements as a vector
- **2795/0008** . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- **2795/0009** . . . viral genome or elements thereof as genetic vector
- **2795/0010** . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- **2795/0011** . . . Special targeting system for viral vectors
- **2795/0012** . . . Methods of production or purification of viral material
- **2795/0013** . . . relating to complementing cells and packaging systems for producing virus or viral particles
- **2795/0014** . . . For redistribution

**C12N**

- **2792/00043** . . . viral genome or elements thereof as genetic vector
- **2792/00044** . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- **2792/00045** . . . Special targeting system for viral vectors
- **2792/00051** . . . Methods of production or purification of viral material
- **2792/00052** . . . relating to complementing cells and packaging systems for producing virus or viral particles
- **2792/00061** . . . Methods of inactivation or attenuation
- **2792/00062** . . . by genetic engineering
- **2792/00063** . . . by chemical treatment
- **2792/00064** . . . by serial passage
- **2792/00071** . . . Demonstrated in vivo effect
- **2792/00088** . . . For redistribution
- **2792/10011** . . . Fuselloviridae
- **2792/10021** . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- **2792/10022** . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- **2792/10023** . . . Virus like particles [VLP]
- **2792/10031** . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- **2792/10032** . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- **2792/10033** . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- **2792/10034** . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- **2792/10041** . . . Use of virus, viral particle or viral elements as a vector
- **2792/10042** . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- **2792/10043** . . . viral genome or elements thereof as genetic vector
- **2792/10044** . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- **2792/10045** . . . Special targeting system for viral vectors
- **2792/10051** . . . Methods of production or purification of viral material
- **2792/10052** . . . relating to complementing cells and packaging systems for producing virus or viral particles
- **2792/10061** . . . Methods of inactivation or attenuation
- **2792/10062** . . . by genetic engineering
- **2792/10063** . . . by chemical treatment
- **2792/10064** . . . by serial passage
- **2792/10071** . . . Demonstrated in vivo effect
- **2792/10088** . . . For redistribution
- **2792/12000** . . . Guttaviridae
- **2792/12011** . . . Bacteriophages
- **2792/12021** . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- **2792/12022** . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- **2792/12023** . . . Virus like particles [VLP]
- **2792/12031** . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- **2792/12032** . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- **2792/12033** . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- **2792/12034** . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- **2792/12041** . . . Use of virus, viral particle or viral elements as a vector
- **2792/12042** . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- **2792/12043** . . . viral genome or elements thereof as genetic vector
- **2792/12044** . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- **2792/12045** . . . Special targeting system for viral vectors
- **2792/12051** . . . Methods of production or purification of viral material
- **2792/12052** . . . relating to complementing cells and packaging systems for producing virus or viral particles
- **2792/12061** . . . Methods of inactivation or attenuation
- **2792/12062** . . . by genetic engineering
- **2792/12063** . . . by chemical treatment
- **2792/12064** . . . by serial passage
- **2792/12071** . . . Demonstrated in vivo effect
- **2792/12088** . . . For redistribution
2795/00063 . . . . by chemical treatment
2795/00064 . . . . by serial passage
2795/00071 . . . . Demonstrated in vivo effect
2795/00088 . . . . For redistribution
2795/10111 . . . . dsDNA Bacteriophages
2795/10021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/10022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/10023 . . . . Virus like particles [VLP]
2795/10031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/10032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/10033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/10034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/10041 . . . . Use of virus, viral particle or viral elements as a vector
2795/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/10043 . . . . viral genome or elements thereof as genetic vector
2795/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/10045 . . . . Special targeting system for viral vectors
2795/10051 . . . . Methods of production or purification of viral material
2795/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2795/10061 . . . . Methods of inactivation or attenuation
2795/10062 . . . . by genetic engineering
2795/10063 . . . . by chemical treatment
2795/10064 . . . . by serial passage
2795/10071 . . . . Demonstrated in vivo effect
2795/10088 . . . . For redistribution
2795/10111 . . . . Myoviridae
2795/10121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/10122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/10123 . . . . Virus like particles [VLP]
2795/10131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/10132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/10133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/10134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/10141 . . . . Use of virus, viral particle or viral elements as a vector
2795/10142 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/10143 . . . . viral genome or elements thereof as genetic vector
2795/10144 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/10145 . . . . Special targeting system for viral vectors
2795/10151 . . . . Methods of production or purification of viral material
2795/10152 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2795/10161 . . . . Methods of inactivation or attenuation
2795/10162 . . . . by genetic engineering
2795/10163 . . . . by chemical treatment
2795/10164 . . . . by serial passage
2795/10171 . . . . Demonstrated in vivo effect
2795/10188 . . . . For redistribution
2795/10211 . . . . Podoviridae
2795/10221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/10222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/10223 . . . . Virus like particles [VLP]
2795/10231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/10232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/10233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/10234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/10241 . . . . Use of virus, viral particle or viral elements as a vector
2795/10242 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/10243 . . . . viral genome or elements thereof as genetic vector
2795/10244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/10245 . . . . Special targeting system for viral vectors
2795/10251 . . . . Methods of production or purification of viral material
2795/10252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2795/10261 . . . . Methods of inactivation or attenuation
2795/10262 . . . . by genetic engineering
2795/10263 . . . . by chemical treatment
2795/10264 . . . . by serial passage
2795/10271 . . . . Demonstrated in vivo effect
2795/10288 . . . . For redistribution
2795/10311 . . . . Siphoviridae
2795/10321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/10322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/10323 . . . . Virus like particles [VLP]
2795/10331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Methods of inactivation or attenuation

- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Methods of production or purification of viral material
- Special targeting system for viral vectors
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Use of virus as therapeutic agent, other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Viruses like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Methods of inactivation or attenuation
- by serial passage
- by genetic engineering
- by chemical treatment
- by serial passage
- Demonstrated in vivo effect
- For redistribution
- Inoviridae
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Viruses like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Use of virus, viral particle or viral elements as a vector
- virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- viral genome or elements thereof as genetic vector
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Special targeting system for viral vectors
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Use of virus, viral particle or viral elements as a vector
- virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- viral genome or elements thereof as genetic vector
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- Methods of inactivation or attenuation
- by serial passage
- by genetic engineering
- by chemical treatment
- by serial passage
- Demonstrated in vivo effect
- For redistribution
- Inoviridae
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Viruses like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles

C12N
Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

ssRNA Bacteriophages negative-sense

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

ssRNA Bacteriophages positive-sense

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

ssRNA Bacteriophages negative-sense

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

ssRNA Bacteriophages positive-sense

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N
2795/18088 . . . For redistribution
2795/18111 . . . Leviviridae
2795/18121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/18122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/18123 . . . Virus like particles [VLP]
2795/18131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/18132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/18133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/18134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/18141 . . . Use of virus, viral particle or viral elements as a vector
2795/18142 . . . Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/18143 . . . Viral genome or elements thereof as genetic vector
2795/18144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/18145 . . . Special targeting system for viral vectors
2795/18151 . . . Methods of production or purification of viral material
2795/18152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2795/18161 . . . Methods of inactivation or attenuation
2795/18162 . . . by genetic engineering
2795/18163 . . . by chemical treatment
2795/18164 . . . by serial passage
2795/18171 . . . Demonstrated in vivo effect
2795/18188 . . . For redistribution

2799/00 Uses of viruses

WARNING
From March 15, 2012 codes in the range C12N 2799/00 - C12N 2799/06 are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in C12N 2710/00-C12N 2795/00.

2799/02 . . . as vector
2799/021 . . . for the expression of a heterologous nucleic acid
2799/022 . . . where the vector is derived from an adenovirus
2799/023 . . . where the vector is derived from a poxvirus
2799/025 . . . where the vector is derived from a parvovirus
2799/026 . . . where the vector is derived from a baculovirus
2799/027 . . . where the vector is derived from a retrovirus
2799/028 . . . where the vector is derived from a herpesvirus
2799/04 . . . in vivo
2799/06 . . . in vitro

2800/00 Nucleic acids vectors
2800/10 . . . Plasmid DNA
2800/101 . . . for bacteria
2800/102 . . . for yeast

2800/103 . . . for invertebrates
2800/105 . . . for insects
2800/106 . . . for vertebrates
2800/107 . . . for mammalian
2800/108 . . . episomal vectors
2800/20 . . . Pseudochromosomes, minichromosomes
2800/202 . . . of bacteriophage origin
2800/204 . . . of bacterial origin, e.g. BAC
2800/206 . . . of yeast origin, e.g. YAC, 2u
2800/208 . . . of mammalian origin, e.g. minichromosome
2800/22 . . . Vectors comprising a coding region that has been codon optimised for expression in a respective host
2800/24 . . . Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
2800/30 . . . Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
2800/40 . . . Systems of functionally co-operating vectors
2800/50 . . . Vectors for producing vectors
2800/60 . . . Vectors containing traps for, e.g. exons, promoters
2800/70 . . . Vectors containing special elements for cloning, e.g. topoisoform, adaptor sites
2800/80 . . . Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
2800/90 . . . Vectors containing a transposable element
2800/95 . . . Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers

2810/00 Vectors comprising a targeting moiety
2810/10 . . . Vectors comprising a non-peptidic targeting moiety
2810/40 . . . Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
2810/405 . . . Vectors comprising RGD peptide
2810/50 . . . Vectors comprising as targeting moiety peptide derived from defined protein
2810/55 . . . from bacteria
2810/60 . . . from viruses
2810/6009 . . . dsDNA viruses
2810/6018 . . . Adenoviridae
2810/6027 . . . ssDNA viruses
2810/6036 . . . DNA rev transcr viruses
2810/6045 . . . RNA rev transcr viruses
2810/6054 . . . Retroviridae
2810/6063 . . . ds RNA viruses
2810/6072 . . . negative strand RNA viruses
2810/6081 . . . rhabdoviridae, e.g. VSV
2810/609 . . . positive strand RNA viruses
2810/65 . . . from plants
2810/70 . . . from fungi
2810/75 . . . from invertebrates
2810/80 . . . from vertebrates
2810/85 . . . mammalian
2810/851 . . . from growth factors; from growth regulators
2810/852 . . . from cytokines; from lymphokines; from interferons
2810/853 . . . from tumor necrosis factor, TNF
2810/854 . . . from hormones
2810/855 . . . from receptors; from cell surface antigens; from cell surface determinants
2810/856 . . . from integrins
2810/857 . . . from blood coagulation or fibrinolysis factors
2810/858 . . . from apolipopptides
2810/859 . . . from immunoglobulins
**2820/00** Vectors comprising a special origin of replication system

- inducible or controllable
- cell-cycle regulated
- tissue or cell-specific
- multiple origins of replication
- from bacteria
- from viruses
- from plants
- from fungi
- yeast
- S. cerevisiae
- S. pombe
- C. albicans
- from invertebrates
- from vertebrates
- mammalian
- avian

**2830/00** Vector systems having a special element relevant for transcription

- controllable enhancer/promoter combination
- inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- tet inducible enhancer/promoter combination
- repressible enhancer/promoter combination, e.g. KRAB
- tet repressible
- cell cycle specific enhancer/promoter combination
- cell type or tissue specific enhancer/promoter combination
- chimeric enhancer/promoter combination
- transcription of more than one cistron
- bidirectional
- being an enhancer not forming part of the promoter region
- being an enhancer forming part of the promoter region
- being a transcription initiation element
- being a transcription termination element
- being a stuffer
- being an insulator
- being an intron or intervening sequence for splicing and/or stability of RNA
- elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
- regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- regulating RNA stability, not being an intron, e.g. poly A signal
- encoding ribozyme for self-inactivation
- from bacteria
- from viruses
- from plants
- yeast
- S. cerevisiae
- S. pombe
- C. albicans
- from invertebrates

NOTE: This group is for classification of patent and non-patent literature documents. For non-patent literature only, the CPC groups cover classification of the non-patent literature documents.

**2840/00** Vectors comprising a special translation-regulating system

- controllable or inducible
- cell cycle specific
- tissue or cell specific
- regulates levels of translation
- inhibiting translation
- enhancing translation
- inhibiting translational read-through
- translation of more than one cistron
- having an IRES
- having multiple IRES
- being a specific part of the splice mechanism, e.g. donor, acceptor
- for trans-splicing, e.g. polypyrimidine tract, branch point splicing
- utilisation of non-ATG initiation codon

**2999/00** Further aspects of viruses or vectors not covered by the C12N 2700/00 or C12N 2800/00 series

NOTES

1. This group is for classification of patent and non-patent literature documents.
2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.

- Adverse teaching
- Biological teaching, e.g. a link between protein and disease, new virus causing pandemic
- Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals

**2830/00**

- from vertebrates
- from mammalian
- avian

**2840/00**

- from vertebrates
- from mammalian
- avian

**2999/00**

- from vertebrates
- from mammalian
- avian